## 1. General information

*Personal details*

| | |
|---|---|
| Name | Qiuwei Abdullah Pan |
| Male/female | M |
| Date of birth | 31-12-1981 |
| Address for correspondence | Narcissenstraat 62A<br>3073CP Rotterdam, The Netherlands |
| Telephone | +31 107037502 |
| E-mail | q.pan@erasmusmc.nl |
| Professional web profiles | https://scholar.google.nl/citations?user=Gh0ropcAAAAJ&hl=en<br>https://www.researchgate.net/profile/Qiuwei-Pan |
| Academic education and degrees<br>What, When and Where | 2000 – 2004: Bachelor Degree, Northwest Minzu University, China.<br>2004 – 2007: Master Degree (Honor), Zhejiang Sci-Tech University, China.<br>2007 - 2012: PhD Degree, Department of Gastroenterology and Hepatology, Erasmus MC- University Medical Center Rotterdam, The Netherlands |
| Doctorate | PhD |
| University | Erasmus University Rotterdam |
| Date | 22-02-2012 |
| Supervisor(s) | Prof. dr. L. J. W. van der Laan, Prof. dr. H. L. A. Janssen & Prof. dr. H. W. Tilanus |
| Title of thesis | Novel Anti-viral Strategies for Hepatitis C |

*Work experience and appointments since graduation (dates, full or part-time (fte) and permanent or fixed-term position)*

01-2016-----: Group Leader (full-time permanent position), at the Department of Gastroenterology and Hepatology, Erasmus MC- University Medical Center Rotterdam, The Netherlands

03-2012---12, 2015: Junior Group Leader (full-time fixed-term position), at the Department of Gastroenterology and Hepatology, Erasmus MC- University Medical Center Rotterdam, The Netherlands

## 2. Three scientific achievements that you are most proud of (max 120 words)

- Pioneered translational research of hepatitis E. The studies on ribavirin and immunosuppressants in HEV experimental models have supported the off-label use of ribavirin for treating chronic HEV patients, guided the optimal choice of immunosuppressive medication for HEV-infected organ recipients, and inspired follow-up clinical studies in the field.
- Characterized the quiescent and proliferating stem cell populations in the liver and identified LGR5 marked tumor-initiating cells in liver cancer that can be therapeutically targeted.
- Recognized the association of healthcare resources and fatality rate at very early stage of COVID-19 pandemic, which have been validated in many follow-up studies across the globe; foresee the relevance of studying seasonal coronaviruses and is investigating pan-coronavirus therapies that can treat circulating but also future emerging coronaviruses.

## 3. Research

*Brief summary of research over the last five years (max. 200 words)*

Over the past years, my research commitments with multidisciplinary features have allowed me to develop competencies in research of

major global health challenges with main focus on liver diseases. Shortly after my PhD defence, I initiated translational research of hepatitis E virus (HEV) infection. So far, I have contributed over 50 publications to this topic alone with major contributions to understanding the epidemiology, virus-host interactions and developing antiviral therapy. My team has extensively revealed the insight of therapeutic and biological importance of antiviral interferon response in limiting HEV infection. Our published translational studies on ribavirin and immunosuppressants in HEV experimental models have supported the off-label use of ribavirin for treating chronic HEV patients, guided the optimal choice of immunosuppressive medication for HEV-infected organ recipients, and inspired follow-up clinical studies in the field. I have also developed research lines in studying fatty liver disease and liver cancer. I have explored the applications of organoids technology for modelling fatty liver, liver cancer and virus research. In response to COVID-19, which is also relevant to gastrointestinal and liver diseases, my team immediately initiated coronavirus research taking multidimensional approaches, aiming at benefiting both the infected patients and the society at large.

*Thesis supervised*

as 'Co-promotor'

- **Xumin Ou**, Title "Translational Decoding in Viral Infection and Cancer Development", 16th, Nov. 2021
- **Peifa Yu**, Title "Understanding Norovirus-Host Interactions: Implications for Developing Novel Antiviral Strategies", 14th, Sep. 2021
- **Zhijiang Miao**, Title "Eliminating Hepatitis D and E: From Epidemiology to Antiviral Therapy", 7th, Sep. 2021
- **Jiaye Liu**, Title: "Viral hepatitis and fatty Liver Disease in Liver Cancer: Two Sides of the Coin", 15th, Dec. 2020
- **Sunrui Chen**, Title: "Facing the Resurgence of Rotavirus: Development of Novel Antiviral Agents", 15th, Dec. 2020
- **Meng Li**, Title: "Mitochondria, Inflammation and Stem Cells in Gastrointestinal and Hepatic Disease", 8th, July, 2020
- **Changbo Qu**, Title: "Hepatitis E Virus Infection and the Treatment", 16th, Oct. 2019
- **Buyun Ma**, Title: "Counterbalancing Cancer Growth: Harnessing Intrinsic Regulatory Pathways for Novel Anti-oncogenic Strategies", 11th, Sep. 2019
- **Wen Dang**, Title: "Development of antivirals against norovirus: linking the bench to the bedside", 12th, Sep. 2018
- **Mohamad Saifudin Hakim**, Title: "Hepatic and Enteric Viral Infections: Molecular Epidemiology, Immunity and Antiviral Therapy", 12th, Sep. 2018
- **Wenshi Wang**, Title: "Development of novel anti-viral strategies for hepatitis E", 6th, Feb. 2018
- **Wanlu Cao**, Title: "Dynamics of stem cells in liver homeostasis, injury and carcinogenesis", 6th, Feb. 2018
- **Juan Li**, Title: "Viral infection and hepatocellular carcinoma". 14th, Nov. 2017
- **Yuebang Yin**, Title: "Modeling infection and antiviral therapy of enteric viruses using primary intestinal organoids", 27th, June, 2017
- **Lei Xu**, Title: "Interferon-stimulated Genes and Their Role in Controlling Hepatitis E Virus", 27th, June, 2017
- **Xinying Zhou**, Title: "Hepatitis E Virus Infection: Pathogenesis and Therapy", 27th, Sep. 2016
- **Yijin Wang**, Title: "Development of Antiviral Therapy against Hepatitis E Virus Infection: On the Basis of Host Factors", 27th, Sep. 2016
- **Kan Chen**, Title: "Challenges in cancer therapy: molecular targets, signalling pathways and personalization", 21st, June, 2016
- **Pratika Yuhyi Hernanda**, Title: "Liver cancer and its tumor microenvironment: the role of mesenchymal stromal cells and SMADs", 15th, Oct. 2014

*Grant allocation*

In total, about 2.2 M€ (over 2 M€ as personal grant).

| Period (from – to) | Funding source and project code | Own share of grant (€) | Total grant (€) | Project title | Role of PI* |
|---|---|---|---|---|---|
| 2019-2024 | NWO Vidi grant | €800,000 | €800,000 | Repurposing FDA-approved drugs for treating hepatitis E virus infection | principal investigator |
| 2017-2022 | Dutch Cancer society, Young Investigator Grant | €549,000 | €549,000 | Identification of tumor-initiating cells in liver cancer and their interactions with hepatitis viruses | principal investigator |

| | | | | | |
|---|---|---|---|---|---|
| 2015-2017 | Erasmus MC Mrace pilot grant | €50,000 | €50,000 | Identify the active component(s) from a plant extract that exerts specific antiviral activity against hepatitis E | principal investigator |
| 2014-2017 | Daniel den Hoed Foundation Centennial Fellowship | €250,000 | €250,000 | Identify the stem of hepatocellular carcinoma | principal investigator |
| 2013-2017 | Dutch Digestive Disease Foundation, Career Development Grant | €250,000 | €250,000 | Identification of remedies against emerging gastrointestinal and hepatic viruses by high-throughput screening of off-patent drug library | principal investigator |
| 2013-2014 | European Association for the Study of the Liver, Sheila Sherlock Fellowship | €40,000 | €40,000 | Identification of Inhibitors of Hepatitis E virus Replication and of Host Factors Involved in Its Infection | Training |
| 2013 | International Liver Transplantation Society, International Travel Scholar Grant | $10,000 | $10,000 | Unveiling the Effects and Mechanisms of Immunosuppressants on Hepatocellular Carcinoma | Training |
| 2013 | ZonMw, Meer Kennis met Minder Dieren program | €9,000 | €9,000 | Investigate the effects of Mesenchymal stem cells on liver cancer | principal investigator |
| 2012-2015 | NWO Veni grant | €243,300 | €243,300 | Combating hepatitis C virus infection using RNAi-producing stem cell therapy | principal investigator |

** examples': principal investigator, project leader, project manager, coordinator, work package leader, etc.*

*Active main (inter)national collaborations (collaborator, topic, institute)*

*International*

- Dr. Denis E Kainov, Norwegian University of Science and Technology, collaborating on antiviral drug screening (e.g. Antiviral Res. 2020 Dec;184:104967; Antiviral Res. 2020 Aug;180:104823. Sci Adv. 2022)
- Dr. Mirza S Baig, Indian Institute of Technology Indore, collaborating on virtual drug screening (e.g. Sci Rep. 2018 Aug 20;8(1):12471; Sci Rep. 2021 Dec 6;11(1):23465; Virology. 2021 Dec;564:33-38.)
- Dr. Yijin Wang (former PhD student), Southern University of Science and Technology, China, collaborating on HEV animal model and patient materials/information (e.g. EBioMedicine. 2018 Oct;36:122-130; Gastroenterology. 2018 Mar;154(4):1199-1201; Hepatology. 2022 Jan;75(1):196-212; Sci Adv. 2022)
- Prof. Nassim Kamar, Département de Néphrologie et Transplantation d'Organes CHU Rangueil, France, collaborating on hepatitis E clinical research (e.g. Antiviral Res. 2022 Jan;197:105228; Liver Int. 2019 Dec;39(12):2291-2300; Hepatology. 2019 Apr;69(4):1846-1847; Lancet Gastroenterol Hepatol. 2017 Mar;2(3):154-155.)

*National*

- Prof. Luc van der Laan, Department of Surgery, Erasmus MC, collaborating on liver organoids technology (e.g. Cell Mol Gastroenterol Hepatol. 2021 Oct 23;13(2):541-564; mBio. 2020 Aug 25;11(4):e01968-20; Nat Commun. 2020 Apr 23;11(1):1961.)
- Dr. Bart Haagmans, Viroscience department, Erasmus MC, collaborating on SARS-CoV-2 (e.g. Cell Research 2022; EBioMedicine. 2022, under revision)
- Dr. Robbert J. Rottier, Department of Pediatric Surgery, Erasmus MC, collaborating on human airway organoids technology (e.g. Cell Research 2022; EBioMedicine. 2022, under revision)
- Dr. Ruchi Bansal, University of Twente, collaborating on macrophage and inflammation (e.g. Gut Microbes. Jan-Dec 2021;13(1):1959839.)

*International research visits > 1 month (institute, dates)*

- 07-2018 – 06-2021: Distinguished Visiting Professor (flexible visiting); Biomedical Research Center, Northwest Minzu University, Lanzhou, China
- 01-2013 – 12-2014: Visiting Professor (Part-time research); Laboratory of Virology and Chemotherapy; Rega Institute for Medical Research, University of Leuven, Belgium; conducting high-throughput antiviral drug screening; supported by the EASL fellowship
- 09-2013 – 08-2014: Guest scientist (flexible visiting) at LKS Faculty of Medicine, the University of Hong Kong; involved in liver cancer research; supported by the ILTS International Travel Scholar Grant

*Patents*

*Published patent: https://patents.google.com/patent/WO2010053350A1/e*

Luc J.W. van der Laan, **Qiuwei Pan**, Meindert Johannes Crop. 2008, Inhibition of viral infection and replication by mesenchymal stem cells (msc) and msc-derived products. Patent application No.: PCT/NL2008/050711. Pub. No.: WO/2010/053350.

*[**Significance:** Discovered completely new modalities for treating hepatitis C virus infection]*

## 4. Teaching

*Brief summary of teaching over the last five years (max. 200 words)*

Over the past years, my main focus is training PhD students, postdocs as well as visiting scientists in my group. I developed “personalized” training approaches aiming at improving their research and communication skills, as well as better preparing their future career development. In total, I have trained 19 former and 8 ongoing PhD students. In 2018 and 2019, I have coordinated the training of 6 Junior Med School students in my group during the summer season. Because of my Dutch language barrier, I actively contribute to English-based courses within Erasmus MC and outside the institute. As a distinguished visiting professor at Northwest Minzu University China for three years, I had strategically advised the development of courses for a Research Master program. Currently, I am coaching international Master students within Erasmus MC to cope with the COVID-19 pandemic.

*Managing/coordinating courses/programmes (course, target group, ECTS, dates)*

- 2012 – current: Training individual PhD students through weekly meeting and discussion; in total, trained 19 former and 8 ongoing PhD students.
- 2017 – 2019: Training a 2-year visiting PhD student, Qin Yang, from China.
- 2018: Coordinating the English Social Skills course at MDL lab for the first-year international PhD students.
- 2016 – 2017 (6 months): Training a visiting scientist, Aqsa Ikram, from Pakistan.

*Developing courses/programmes (course, target group, ECTS, dates)*

- 2020 – Current: Coaching international Master students within Erasmus MC to cope with the COVID-19 pandemic.
- 2022: Developed one Continuing Medical Education (EME) exam for Clinical Gastroenterology and Hepatology, a prestigious journal of the field. This exam (1 Credit Hour) is related to our published paper “Estimating global prevalence of metabolic dysfunction-associated fatty liver disease in overweight or obese adults”, which has been chosen to have accompanying CME exercises.

- 2018 – 2021: Advising the development of courses for a Research Master program, Biomedical research Center, Northwest Minzu University, China.
- 2018 – 2019: Developed program for two PhD students to train 6 Junior Med School students, for 4 weeks with 20 hours/week for each student (in total, 8.7 ECTs).

*Lecturing (course, target group, ECTS, dates). An overview of lectures or an IRIS printout may optionally be included in Annex 3.*

- 08-11-2021, "Evaluating the efficacy of COVID-19 vaccination in IBD patients beyond antibody titers", Regionale IBD avond, for IBD specialists and trainees, Van der Valk Hotel, Ridderkerk, The Netherlands.
- 15-10-2018, "An Introduction to Biomedical Research & Research Integrity" (3 hours). Research Master Education program, Biomedical Research Center, Northwest Minzu University, Lanzhou, China.
- 25-08-2017, "Viral Hepatitis and Liver Cancer: Perspectives of Translational Research", for clinical and research trainees, Beijing 302 hospital, China.
- 21-02-2017, "Modeling viral infection in organoids", Winter course Infection & Immunity Master Program, Erasmus MC, Rotterdam, The Netherlands.
- 17-05-2016, "Hepatitis E: an Emerging Global health Issue", for Master and PhD students, Faculty of Life Science and Technology, Kunming University of Science and technology, China.
- 22-10-2015, "Modeling rotavirus infection and antiviral therapy using primary intestinal organoids", at the workshop 'Application of human 3D culture models for virus research', Amsterdam, The Netherlands.
- 04-11-2014, "Supervision in science: Perspective of Junior Investigator", at the Post-Doc Network Meeting, Erasmus MC, Rotterdam, The Netherlands.
- 26-09-2014, "Modeling virus infections by stem cell-derived cell culture systems", at Stem cell course, organized by Erasmus MC Stem Cell Institute, Rotterdam, The Netherlands.
- 08-05-2013, "Viral hepatitis and liver cancer" for Bachelor and Master students at School of Life Science, Zhejiang Sci-Tech University, China.
- 02-05-2013, "Antiviral therapy against viral hepatitis" for Bachelor and Master students at Life Science and Engineering College of Northwest University for Nationalities, China.

*Basic teaching qualification (BKO)*[1]

N/A

*Additional teaching qualifications (SKO, LOL)*[2]

N/A

*Evaluation scores (received from students, coordinators, and/or program directors) on teaching and implemented improvements*[3]

N/A

## 5. Training

*Courses (max. 200 words)*

I have taken various courses mainly from the Erasmus MC MolMed graduate school, including laboratory animal science (Art. 9), Animal imaging workshop, Partek data analysis courses (three series), Basic data analysis on gene expression arrays, Valorisation workshop, Photoshop CS3 workshop and Grant proposal writing workshop. To better integrate in the Dutch society, I have taken the inburgering course at Tornate Trainingen and I have obtained the inburgering diploma in 2014. To improve my research and supervision skills, I have visited Rega Institute for Medical Research, University of Leuven in Belgium for learning the principle and technique of antiviral drug

[1] (Compulsory) basic qualification for didactic competencies for all lecturers at Erasmus MC ('basis kwalificatie onderwijs'). For more information contact bko@erasmusmc.nl, https://intranet.erasmusmc.nl/onderwijsbeleidenadvies/bko/.

[2] : Only required if you apply for UHD or professorship with an educational profile

[3] : Only required if you apply for UHD or professorship with an educational profile

screening. I now have implemented this technique is my own research group for identifying antiviral drugs against HEV, rotavirus and coronaviruses. I also visited and was trained at LKS Faculty of Medicine, University of Hong Kong during 2013-2014 on research of liver cancer in liver transplantation setting. These two international visits were supported by the training fellowships from European Association for the Study of the Liver and International Liver Transplantation Society, respectively.

## 6. Patient Care

*Brief summary of patient care responsibilities over the last five years (max. 200 words)*

N/A

## 7. Clinical Training

N/A

## 8. Management

*Brief summary of management over the last five years (max. 200 words)*

Over the past years, the size of my group ranged from about 5 to 15 members, and currently is stabilized with about 10 members. My primary task is supervising PhD students and postdocs. In total, 19 PhD students have successfully defended their theses and 8 remain at training. Besides guiding their daily research, I pay specific attention to facilitate their future career development. For example, Dr. Y. Wang (graduated in 2016), has become Associate Professor/group leader at Southern University of Science and Technology, a rapidly growing new research university in China. Dr. W. Wang was awarded the EASL Sheila Sherlock Fellowship (€120,000) during training in my group, which supported his further career development at a top hepatitis D virus research lab in University Hospital Heidelberg, and recently he has established his own research group in China. In addition, I am also supervising the BSL2 lab at our department, and responsible for three members (2 PhD students and 1 technician) from my group working in BSL3 lab at the core facility. Currently, I am launching the Global Hepatitis E Platform. I manage this platform to engage multi-stakeholders for advancing hepatitis E research, education, public health and patient care.

*Size (fte) and composition of own research group*

| | |
|---|---|
| Scientific personnel | 8 PhD candidates |
| Other | 1 technician; 1 Master student |

*Supervision*

| | |
|---|---|
| Number of Master students | 2 |
| Number of PhD candidates | 19 successfully defended thesis; 8 in training |
| Number of Postdocs | 2 |

## 9. Institutional responsibilities

2018 – 2021 As distinguished visiting professor, strategically advising on launching a new biomedical institute, recruiting/training young talents and developing educational programs for graduate students; at Biomedical Research Center, Northwest Minzu University, Lanzhou, China.

## 10. Professional societies

### *Commissions of trust*

### *Editorial board*

2016 – Editorial Board Member, Scientific Reports, handled over 50 manuscripts

2021 – Editorial Board Member/Academic Editor, Journal of Clinical and Translational Hepatology, handled 2 manuscripts

### *Scientific advisory board*

N/A

### *Review board*

2020: Evaluation committee of the SNSF special call on coronaviruses, the Swiss National Science Foundation

### *Review panel member*

- 2020 – Grant review, Health and Medical Research Fund (HMRF), Hong Kong
- 2020: Grant review, Sir Jules Thorn Award grant programme, UK. Funding of £1.7m for young talent of translational biomedical research
- 2019: Grant review, Cancer Research Wales, UK
- 2017 – Grant review, Swiss National Science Foundation
- 2017 – Grant review, The French National Research Agency
- 2017 – Grant review, The Dutch Cancer Society
- 2017: Grant review, the USIAS FELLOWSHIP program, University of Strasbourg, France
- 2016 – Grant review, the Austrian Science Fund
- 2016 – Grant review, The Israel Science Foundation
- 2012 – Reviewer for numerous scientific journals, including top journals such as Gastroenterology, Hepatology, Journal of Hepatology, Hepatology, Lancet Infectious Diseases, Emerging Infectious Diseases, Clinical Infectious Diseases, Cell Reports, Nature Communications

### *Organisation of scientific meetings*

- 28-30, August, 2019, Organizer/Session Chair/Opening Lecture, The 2019 International Symposium on Biomedicine and Biomaterials (ISBB), Lanzhou, China (about 300 participants)
- 14-16, February 2019, Faculty/Session Chair, the first HEV symposium, Essen, Germany (about 200 participants)
- 24-25, October, 2015, Scientific committee/Session Chair/Speaker, International Conference on Precision Medicine of Cancer Diagnosis and Treatment, Hangzhou, China (about 200 participants)

### *Memberships*

### *Board membership*

*N/A*

### *Membership*

- 2020 – Member, American Society for Microbiology
- 2012 – Member, European Association for the Study of the Liver
- 2012 – 2014 Member, the International Liver Transplantation Society
- 2008 – Member, The Dutch Hepatology Association

## 11. Societal quality of own research[4] (max. three examples)

- 2022, Studying direct-acting antiviral drugs for treating SARS-CoV-2 Omicron variant was highlighted by ***Amazing Erasmus MC*** (https://amazingerasmusmc.nl/infectie/twee-bestaande-antivirale-middelen-werken-ook-tegen-omikron-variant/)
- 2021, Interviewed by ***Nature*** to explain the new theory and the relevance of seasonal coronaviruses in relation to the COVID-19 pandemic to a broad audience (https://www.nature.com/articles/d41586-020-03519-3 page 390).
- 2013–2014, Invited by Medicin-sans-Fronitiers to advise on the potential off-label treatment of hepatitis E, during the large hepatitis E outbreak in refugee camps in Southern Sudan.

## 12. Honours and awards

- 2021, EASL Emerging Leader Award, a yearly award specifically dedicated to usually one clinician and one scientist (40 years old or less) based on their international liver research achievements to date, by the European Association for the Study of the Liver (over 4,500 members from all over the world). I was awarded based on my outstanding achievement on HEV research.
- 2013, International Travel Scholar Award, the International Liver Transplantation Society
- 2013, Best PhD Thesis Award, Erasmus MC MolMed Postgraduate School
- 2012, Publication of the Year Award, the Dutch Society for Organ Transplantation
- 2009, Rising Star Award, the International Liver Transplantation Society
- 2008; 2009, Best Abstract Award (two times); the annual meeting of the Dutch Hepatology Association
- 2012 – ; Award/Prize for my supervised fellows: Two best abstract award from the Dutch Hepatology Association; Best publication award from the Dutch Microbiology Society; Best PhD Thesis award from the Erasmus MC MolMed Postgraduate school; Best PhD thesis award from the Dutch Digestive Disease Association; about 10 young investigator bursary award from the annual meetings of EASL

## 13. Side positions

**- General**

I am currently launching the Global Hepatitis E Platform (GHEP). As the founder, I will coordinate this platform to engage the multi-stakeholders for advancing hepatitis E research, education, public health and patient care.

**- External consultancies (governmental/industry)**

N/A

## 14. Annex 1 Publications

*H-index Web of Science[5]*

H-index (all publications) 35

*Average citations per item[6]*

21

[4] Erasmus MC has formulated 11 societal impact indicators: publications in Dutch journals, articles in newspapers & interviews on radio and television, websites for a wide audience, education based on results own research, books for professionals, authorships of policy documents and instruments, **authorships** of medical standards, granted patents, products implemented in the health care system/market, contribution to the employment of city/region Rotterdam and contact with stakeholders by networking and public-private cooperation.

[5] H-index: a scholar with an index of h has published h papers each of which has been cited by others at least h times. Thus, the h-index reflects both the number of publications and the number of citations per publication. Calculate the index on http://www.erasmusmc.nl/medbib/ quick link 'Web-of-Knowledge': select your publications and click on 'create citation report'. Specify the number of first and last authorships of publications within the h-index. For more information: https://www.erasmusmc.nl/medbib/Publiceren/

[6] Calculate the score on https://www.erasmusmc.nl/medbib/ quick link Web-of-Knowledge: select your publications and click on 'create citation report'.

*Person-years of research*[7]

10

*Main ISI subject category*[8]

Gastroenterology and Hepatology

*Publication list*[9]

| | |
|---|---|
| - # International full articles (any position) | 206 <List of publication in attachment> |
| - # International full articles (first position) | 20 |
| - # International full articles (last position) | 106 |

Five most influential publications, including number of citations

All five as last/corresponding author (indicated by "*"):

1. Wang Y, Zhou X, Debing Y, Chen K, Van Der Laan LJ, Neyts J, Janssen HL, Metselaar HJ, Peppelenbosch MP, **Pan Q***. Calcineurin inhibitors stimulate and mycophenolic acid inhibits replication of hepatitis E virus. ***Gastroenterology***. 2014 Jun;146(7):1775-83. (IF: **22.7**; top**10%**)
[***Significance****: this together with another study (Zhou…& Pan. J Hepatol. 2014 Oct;61(4):746-54.) demonstrated the differential effects and mechanism-of-actions of different immunosuppressants on hepatitis e virus (HEV) infection in cell culture models. Both are landmark studies in the field, providing key references for optimal choice of immunosuppressive medications for HEV-infected transplantation patients. Citation: 157 google/116 WoS.*]

2. Cao W, Li M, Liu J, Zhang S, Noordam L, Verstegen MMA, Wang L, Ma B, Li S, Wang W, Bolkestein M, Doukas M, Chen K, Ma Z, Bruno M, Sprengers D, Kwekkeboom J, van der Laan LJW, Smits R, Peppelenbosch MP, **Pan Q***. LGR5 marks targetable tumor-initiating cells in mouse liver cancer. ***Nature Communications***. 2020 Apr 23;11(1):1961. (IF: **14.9**; top**10%**)
[***Significance****: this together with another study (Cao…& Pan. Gastroenterology. 2017 Oct;153(4):1133-1147.) characterized the dynamics of quiescent and proliferating stem cells in liver homeostasis, injury and cancer development; identified LGR5 marked liver-tumor initiating cells that can be therapeutically targeted; and importantly mastered the organoids technology for other research lines such as modeling viral infections. Citation: 23 google/14 WoS.*]

3. Li P, Li Y, Wang Y, Liu J, Lavrijsen M, Li Y, Zhang R, Verstegen MMA, Wang Y, Li TC, Ma Z, Kainov DE, Bruno MJ, de Man RA, van der Laan LJW, Peppelenbosch MP, **Pan Q***. Recapitulating hepatitis E virus-host interactions and facilitating antiviral drug discovery in human liver-derived organoids. ***Science Advances***. 2022 Jan 21;8(3):eabj5908. (IF: **14.1**; top**10%**)
[***Significance****: hepatotropic viruses naturally have narrow host and tissue tropisms, challenging the development of robust experimental models. This study successfully established human liver organoids based models for hepatitis E virus infection. These innovative models shall facilitate the study of hepatitis E virus-host interactions and development of antiviral therapies in my group but also in the field in general.*]

[7] Person-years of research is the time you have been employed to do research since your doctorate minus the time you needed for care responsibilities, including parental, maternity and care leave. The person-years of research do not include the time you were appointed to perform management tasks, patient care or teaching.

[8] http://www.erasmusmc.nl/medbib/

[9] Include only manuscripts which have been accepted for publication. Indicate per publication: the ranking of the journal in the research field (quartile and top10%). If a journal fits into more than one research field, indicate only the highest quartile. Mark your own authorship per publication a. For more information: https://www.erasmusmc.nl/medbib/Publiceren/

4. Ji Y, Ma Z, Peppelenbosch MP, **Pan Q***. Potential association between COVID-19 mortality and health-care resource availability. ***Lancet Global Health***. 2020 Apr;8(4):e480. (IF: **26.8**; top**10%**)
[***Significance****: the first to report association between healthcare resource and COVID-19 mortality, followed by many studies worldwide to have confirmed our findings; this study has attracted great attention from academia, authorities and the general public, e.g. Social Media 2,678, Captures 960, News/Blog Mentions 7, Guideline/policy source 11, citation 612 google/321 WoS; these findings provided very early guidance for healthcare authorities and frontline health workers to mitigate medical resource crisis amid the pandemic.*]

5. Li P, Wang Y, Lavrijsen M, Lamers MM, de Vries AC, Rottier RJ, Bruno MJ, Peppelenbosch MP, Haagmans BL, **Pan Q***. SARS-CoV-2 Omicron variant is highly sensitive to molnupiravir, nirmatrelvir, and the combination. ***Cell Research***. 2022 Jan 20. doi: 10.1038/s41422-022-00618-w. (IF: **25.6**; top**10%**)
[***Significance****: the emerging SARS-CoV-2 Omicron variant harbors a large number of mutations that enable its escape from the existing COVID-19 vaccines and overpower the available antibody therapies. This study demonstrated the effectiveness of two clinically available oral direct-acting antiviral agents against the Omicron variant, and the synergistic antiviral activity in combination using relevant experimental models. These findings support the use of molnupiravir and nirmatrelvir for treating Omicron infected patients, and call the initiation of clinical studies to evaluate the combination for treating COVID-19. This research was highlighted by Amazing Erasmus MC to a broad audience (https://amazingerasmusmc.nl/infectie/twee-bestaande-antivirale-middelen-werken-ook-tegen-omikron-variant/).*]

| | |
|---|---|
| National (refereed) full articles | 3 <List of publication in attachment> |
| Books | N/A |
| Contribution to books (e.g. chapters or editorships) | 4 <List of publication in attachment> |
| Other (proceedings, conference reports, abstracts, etc.) | N/A |

## 15. Annex 2 Invited plenary lectures (meeting, dates)

- 28-08-2019, Opening Lecture "An Introduction to Biomedical Research", The 2019 International Symposium on Biomedicine and Biomaterials (ISBB), Lanzhou, China.
- 13-11-2018, invited speaker, "Virus-host interactions and antiviral drug development against hepatitis E virus infection", International Symposium on Infectious Diseases at Delhi NCR, India.
- 06-09-2018, invited keynote speaker, “Prevention and treatment for hepatitis E virus infection: an emerging zoonotic pathogen”, 28th European Congress of Veterinary Internal Medicine for Companion Animals (ECVIM-CA), Rotterdam, The Netherlands.
- 28-07-2018, invited speaker, "Targeting LGR5 liver cancer stem cells", the annual meeting of Society for Molecular Diagnosis, Chinese Research Hospital Association, Changchun China.
- 28-10-2015, invited speaker, "Interferon for treating viral hepatitis: efficacy & mechanism-of-action”, the annual meeting of the Chinese Association of Life-Sciences in the Netherlands (CALN), Rotterdam, The Netherlands.

- 08-10-2015, invited speaker, “Antiviral drug screening for enteric viral infections”, at the annual autumn meeting of the Dutch Gastroenterology and Hepatology Society, Veldhoven, The Netherlands.
- 25-10-2015, speaker, “Therapeutic development for viral hepatitis and liver cancer”, International Conference on Precision Medicine of Cancer Diagnosis and Treatment, Hangzhou, China
- 18-03-2015, Chair lecture "The Changing Face of Hepatitis Research", at the annual meeting of the Dutch Gastroenterology and Hepatology Society, and chair the session "Liver inflammation", Veldhoven, The Netherlands.
- April, 2015, invited speaker, "Identification of Inhibitors of Hepatitis E virus replication and of Host Factors Involved in Its Infection", at the "Fellowship and Registry Grant Presentations" session (for the celebration of the 50th anniversary), the 50th International Liver congress organized by EASL in Vienna, Austria.
- June, 2009, The Rising Star Award Ceremony Lecture "Calcineurin inhibitor tacrolimus does not interfere with the suppression of hepatitis C virus infection by interferon-alpha", at the annual meeting of International Liver Transplantation Society in New York, USA.

## 16. Annex 3 Overview of educational lectures or an IRIS out-print, if available (optional, may also be listed in section 4 and provided in Dutch.)

See section 4

## Publications:

### *International*

**Note:** over 200 publications with 20 first and over 100 last/corresponding (designated as "*") authorships in peer-reviewed international journals were listed based on searching in January 2022. Impact factor (IF) of 2020, and the ranking of the journal in the research field as Q1 and top10% were indicated. In total, 46 publications are in journals ranking top10%.

Pubmed link:

https://pubmed.ncbi.nlm.nih.gov/?term=Pan+Q%5BAU%5D+AND+%28Erasmus%29+OR+Pan%2C+Qiuwei&sort=date&size=200

**2022**

1. Li P, Wang Y, Lavrijsen M, Lamers MM, de Vries AC, Rottier RJ, Bruno MJ, Peppelenbosch MP, Haagmans BL, **Pan Q***.

   SARS-CoV-2 Omicron variant is highly sensitive to molnupiravir, nirmatrelvir, and the combination. ***Cell Res***. 2022 Jan 20. doi: 10.1038/s41422-022-00618-w. (IF: **25.6**; top**10%**)

2. Li P, Li Y, Wang Y, Liu J, Lavrijsen M, Li Y, Zhang R, Verstegen MMA, Wang Y, Li TC, Ma Z, Kainov DE, Bruno MJ, de Man RA, van der Laan LJW, Peppelenbosch MP, **Pan Q***.

   Recapitulating hepatitis E virus-host interactions and facilitating antiviral drug discovery in human liver-derived organoids. ***Sci Adv***. 2022 Jan 21;8(3):eabj5908. (IF: **14.1**; top**10%**)

3. Li Y, Yu P, Kessler AL, Shu J, Liu X, Liang Z, Liu J, Li Y, Li P, Wang L, Wang Y, Ma Z, Liu A, Wang L, Bruno MJ, de Man RA, Peppelenbosch MP, Buschow SI, Wang L*, Wang Y*, **Pan Q***.

   Hepatitis E virus infection activates NOD-like receptor family pyrin domain-containing 3 inflammasome antagonizing interferon response but therapeutically targetable. ***Hepatology***. 2022 Jan;75(1):196-212. (IF: **17.4**; top**10%**)

4. van Kleef LA, Ayada I, Alferink LJM, **Pan Q**, de Knegt RJ.

   Metabolic dysfunction-associated fatty liver disease improves detection of high liver stiffness: The Rotterdam Study. ***Hepatology***. 2022 Feb;75(2):419-429. (IF: **17.4**; top**10%**)

5. Shi S, Verstegen MMA, Roest HP, Ardisasmita AI, Cao W, Roos FJM, de Ruiter PE, Niemeijer M, **Pan Q**, IJzermans JNM, van der Laan LJW.

   Recapitulating Cholangiopathy-Associated Necroptotic Cell Death In Vitro Using Human Cholangiocyte Organoids. ***Cell Mol Gastroenterol Hepatol***. 2022;13(2):541-564. (IF: **9.2**; **Q1**)

6. Li Y, Li P, He Q, Zhang R, Li Y, Kamar N, Peppelenbosch MP, de Man RA, Wang L, **Pan Q***.

   Niclosamide inhibits hepatitis E virus through suppression of NF-kappaB signalling. ***Antiviral Res***. 2022 Jan;197:105228. (IF: **6**; **Q1**)

7. Li Y, Li P, de Man RA, Peppelenbosch MP, **Pan Q***.

   Probing the direct effects of antiretroviral drugs on hepatitis E virus replication in cell culture models. ***Liver Int***. 2022 Jan 22. doi: 10.1111/liv.15168. (IF: **5.8**)

8. Wang L, Li M, Yu B, Shi S, Liu J, Zhang R, Ayada I, Verstegen MMA, van der Laan LJW, Peppelenbosch MP, Cao W, **Pan Q***.

   Recapitulating lipid accumulation and related metabolic dysregulation in human liver-derived organoids. ***J Mol Med***. 2022 Jan 20. doi: 10.1007/s00109-021-02176-x. (IF: **4.6**)

9. Rajpoot S, Solanki K, Kumar A, Zhang KYJ, Pullamsetti SS, Savai R, Faisal SM, **Pan Q**, Baig MS.

   In-Silico Design of a Novel Tridecapeptide Targeting Spike Protein of SARS-CoV-2 Variants of Concern. ***Int J Pept Res Ther***. 2022;28(1):28. (IF: **1.9**)

**2021**

10. Yu P, Miao Z, Li Y, Bansal R, Peppelenbosch MP, **Pan Q***.

    cGAS-STING effectively restricts murine norovirus infection but antagonizes the antiviral action of N-terminus of RIG-I in mouse macrophages. ***Gut Microbes***. 2021 Jan-Dec;13(1):1959839. (IF: **10.2**; top**10%**)

11. Liu J, Ayada I, Zhang X, Wang L, Li Y, Wen T, Ma Z, Bruno MJ, de Knegt RJ, Cao W, Peppelenbosch MP,

Ghanbari M, Li Z, **Pan Q***.

Estimating Global Prevalence of Metabolic Dysfunction-Associated Fatty Liver Disease in Overweight or Obese Adults. ***Clin Gastroenterol Hepatol***. 2021 Feb 20:S1542-3565(21)00208-1. (IF: **11.4**; top**10%**)

12. Li P, Ikram A, Peppelenbosch MP, Ma Z, **Pan Q***.

    Systematically Mapping Clinical Features of Infections With Classical Endemic Human Coronaviruses. ***Clin Infect Dis***. 2021 Aug 2;73(3):554-555. (IF: **9.1**; top**10%**)

13. Ji Y, Li P, Zheng Q, Ma Z, **Pan Q***.

    Distinct effectiveness in containing COVID-19 epidemic: Comparative analysis of two cities in China by mathematical modeling. ***PLOS Glob Public Health***. 2021 1(11): e0000043.

14. Shi S, Chen S, Verstegen MMA, **Pan Q**, van der Laan LJW.

    High Mobility Group Box Protein 1 Release Is an Identified Driver of Inflammation in the Pathogenesis of Biliary Atresia. ***Hepatology***. 2021 Nov;74(5):2920-2921. (IF: **17.4**; top**10%**)

15. Karabegović I, Portilla-Fernandez E, Li Y, Ma J, Maas SCE, Sun D, Hu EA, Kühnel B, Zhang Y, Ambatipudi S, Fiorito G, Huang J, Castillo-Fernandez JE, Wiggins KL, de Klein N, Grioni S, Swenson BR, Polidoro S, Treur JL, Cuenin C, Tsai PC, Costeira R, Chajes V, Braun K, Verweij N, Kretschmer A, Franke L, van Meurs JBJ, Uitterlinden AG, de Knegt RJ, Ikram MA, Dehghan A, Peters A, Schöttker B, Gharib SA, Sotoodehnia N, Bell JT, Elliott P, Vineis P, Relton C, Herceg Z, Brenner H, Waldenberger M, Rebholz CM, Voortman T, **Pan Q**, Fornage M, Levy D, Kayser M, Ghanbari M.

    Epigenome-wide association meta-analysis of DNA methylation with coffee and tea consumption. ***Nat Commun***. 2021 May 14;12(1):2830. (IF: **14.9**; top**10%**)

16. Liu J, Li P, Wang L, Li M, Ge Z, Noordam L, Lieshout R, Verstegen MMA, Ma B, Su J, Yang Q, Zhang R, Zhou G, Carrascosa LC, Sprengers D, IJzermans JNM, Smits R, Kwekkeboom J, van der Laan LJW, Peppelenbosch MP, **Pan Q***, Cao W*.

    Cancer-Associated Fibroblasts Provide a Stromal Niche for Liver Cancer Organoids That Confers Trophic Effects and Therapy Resistance. ***Cell Mol Gastroenterol Hepatol***. 2021;11(2):407-431. (IF: **9.2**; **Q1**)

17. Ge Z, Zhou G, Campos Carrascosa L, Gausvik E, Boor PPC, Noordam L, Doukas M, Polak WG, Terkivatan T, **Pan Q**, Takkenberg RB, Verheij J, Erdmann JI, IJzermans JNM, Peppelenbosch MP, Kraan J, Kwekkeboom J, Sprengers D.

    TIGIT and PD1 Co-blockade Restores ex vivo Functions of Human Tumor-Infiltrating CD8+ T Cells in Hepatocellular Carcinoma. ***Cell Mol Gastroenterol Hepatol***. 2021;12(2):443-464. (IF: **9.2**; **Q1**)

18. Zhang X, Mens MMJ, Abozaid YJ, Bos D, Darwish Murad S, de Knegt RJ, Ikram MA, **Pan Q**, Ghanbari M.

    Circulatory microRNAs as potential biomarkers for fatty liver disease: the Rotterdam study. ***Aliment Pharmacol Ther***. 2021 Feb;53(3):432-442. (IF: **8.2**; **Q1**)

19. Dian Z, Sun Y, Zhang G, Xu Y, Fan X, Yang X, **Pan Q**, Peppelenbosch M, Miao Z.

    Rotavirus-related systemic diseases: clinical manifestation, evidence and pathogenesis. ***Crit Rev Microbiol***. 2021 Sep;47(5):580-595. (IF: **7.6**; **Q1**)

20. Su J, Wang Y, Zhang X, Ma M, Xie Z, **Pan Q**, Ma Z, Peppelenbosch MP.

    Remodeling of the gut microbiome during Ramadan-associated intermittent fasting. ***Am J Clin Nutr***. 2021 May 8;113(5):1332-1342. (IF: **7**; **Q1**)

21. Noordam L, Ge Z, Özturk H, Doukas M, Mancham S, Boor PPC, Campos Carrascosa L, Zhou G, van den Bosch TPP, **Pan Q**, IJzermans JNM, Bruno MJ, Sprengers D, Kwekkeboom J.

    Expression of Cancer Testis Antigens in Tumor-Adjacent Normal Liver Is Associated with Post-Resection Recurrence of Hepatocellular Carcinoma. ***Cancers*** (Basel). 2021 May 20;13(10):2499. (IF: **6.6**; **Q1**)

22. Liu WY, Zhang X, Li G, Tang LJ, Zhu PW, Rios RS, Zheng KI, Ma HL, Wang XD, **Pan Q**, de Knegt RJ, Valenti L, Ghanbari M, Zheng MH.

    Protective association of Klotho rs495392 gene polymorphism against hepatic steatosis in non-alcoholic fatty liver disease patients. ***Clin Mol Hepatol***. 2021 Nov 28. doi: 10.3350/cmh.2021.0301. (IF: **6.1**; **Q1**)

23. Zhang R, Noordam L, Ou X, Ma B, Li Y, Das P, Shi S, Liu J, Wang L, Li P, Verstegen MMA, Reddy DS, van der Laan LJW, Peppelenbosch MP, Kwekkeboom J, Smits R, **Pan Q***.

    The biological process of lysine-tRNA charging is therapeutically targetable in liver cancer. ***Liver Int***. 2021 Jan;41(1):206-219. (IF: **5.8**)

24. Ayada I, van Kleef LA, Alferink LJM, Li P, de Knegt RJ, **Pan Q***.

    Systematically comparing epidemiological and clinical features of MAFLD and NAFLD by meta-analysis: Focusing on the non-overlap groups. ***Liver Int***. 2021 Dec 25. doi: 10.1111/liv.15139. (IF: **5.8**)

25. Miao Z, Zhang R, Yu P, Li Y, **Pan Q***, Li Y*.

    The macrolide antibiotic azithromycin potently inhibits hepatitis E virus in cell culture models. ***Int J Antimicrob Agents***. 2021 Sep;58(3):106383. (IF: **5.3**; **Q1**)

26. Yang Q, Wang L, Liu J, Cao W, **Pan Q**, Li M.

    Targeting the complex I and III of mitochondrial electron transport chain as a potentially viable option in liver cancer management. ***Cell Death Discov***. 2021 Oct 14;7(1):293. (IF: **5.2**)

27. Wang L, Liu J, Miao Z, **Pan Q***, Cao W*.

    Lipid droplets and their interactions with other organelles in liver diseases. ***Int J Biochem Cell Biol***. 2021 Apr;133:105937. (IF: **5.1**)

28. Ou X, Yang Z, Zhu D, Mao S, Wang M, Jia R, Chen S, Liu M, Yang Q, Wu Y, Zhao X, Zhang S, Huang J, Gao Q, Liu Y, Zhang L, Peppelenbosch M, **Pan Q**, Cheng A.

    Tracing genetic signatures of bat-to-human coronaviruses and early transmission of North American SARS-CoV-2. ***Transbound Emerg Dis***. 2021 May 9:10.1111/tbed.14148. (IF: **5**; **Q1**)

29. Zheng Q, Wang X, Bao C, Ji Y, Liu H, Meng Q, **Pan Q***.

    A multi-regional, hierarchical-tier mathematical model of the spread and control of COVID-19 epidemics from epicentre to adjacent regions. ***Transbound Emerg Dis***. 2021 Feb 4:10.1111/tbed.14019. (IF: **5**; **Q1**)

30. Shi S, Wang L, van der Laan LJW, **Pan Q**, Verstegen MMA.

    Mitochondrial Dysfunction and Oxidative Stress in Liver Transplantation and Underlying Diseases: New Insights and Therapeutics. ***Transplantation***. 2021 Nov 1;105(11):2362-2373. (IF: **4.9**)

31. Zhang X, Asllanaj E, Amiri M, Portilla-Fernandez E, Bramer WM, Nano J, Voortman T, **Pan Q**, Ghanbari M.

    Deciphering the role of epigenetic modifications in fatty liver disease: A systematic review. ***Eur J Clin Invest***. 2021 May;51(5):e13479. (IF: **4.9**; **Q1**)

32. Ma ZR, Ma WH, Idris S, **Pan QW**, Baloch Z.

    COVID-19 impact on high school student's education and mental health: A cohort survey in China. ***World J Psychiatry***. 2021 Jun 19;11(6):232-241. (IF: **4.6**)

33. Ma ZR, Idris S, **Pan QW**, Baloch Z.

    COVID-19 knowledge, risk perception, and information sources among Chinese population. ***World J Psychiatry***. 2021 May 19;11(5):181-200. (IF: **4.6**)

34. Wang Y, Li P, Rajpoot S, Saqib U, Yu P, Li Y, Li Y, Ma Z, Baig MS, **Pan Q***.

    Comparative assessment of favipiravir and remdesivir against human coronavirus NL63 in molecular docking and cell culture models. ***Sci Rep***. 2021 Dec 6;11(1):23465. (IF: **4.4**; **Q1**)

35. Li H, Zhang Y, Ma Z, Liu Z, Ikram A, Liu L, Zhao G, **Pan Q**, Baloch Z.

    HEV prevalence and potential risk factors in a large multi-ethnic youth cohort in China. ***Virol J***. 2021 Jan 6;18(1):3. (IF: **4.1**)

36. Ji Y, Li P, Jia Y, Wang X, Zheng Q, Peppelenbosch MP, Ma Z, **Pan Q***.

    Estimating the burden and modeling mitigation strategies of pork-related hepatitis E virus foodborne transmission in representative European countries. ***One Health***. 2021 Nov 18;13:100350. (IF: **3.8**; Q1)

37. Li P, Ji Y, Li Y, Ma Z, **Pan Q***.

    Estimating the global prevalence of hepatitis E virus in swine and pork products. ***One Health***. 2021 Dec 14;14:100362. (IF: **3.8**; **Q1**)

38. Zheng Q, Wang X, Bao C, Ma Z, **Pan Q***.

    Mathematical modelling and projecting the second wave of COVID-19 pandemic in Europe. ***J Epidemiol Community Health***. 2021 Feb 16;75(6):601-3. (IF: **3.7**)

39. Li P, Wang Y, Peppelenbosch MP, Ma Z, **Pan Q***.

Systematically comparing COVID-19 with the 2009 influenza pandemic for hospitalized patients. ***Int J Infect Dis***. 2021 Jan;102:375-380. (IF: **3.6**)

40. Wang Y, Li P, Solanki K, Li Y, Ma Z, Peppelenbosch MP, Baig MS, **Pan Q***.

    Viral polymerase binding and broad-spectrum antiviral activity of molnupiravir against human seasonal coronaviruses. ***Virology***. 2021 Dec;564:33-38. (IF: **3.6**)

41. Ma J, Cheng Y, Su Q, Ai W, Gong L, Wang Y, Li L, Ma Z, **Pan Q**, Qiao Z, Chen K.

    Effects of intermittent fasting on liver physiology and metabolism in mice. ***Exp Ther Med***. 2021 Sep;22(3):950. (IF: **2.4**)

42. Ma Z, Idris S, Zhang Y, Zewen L, Wali A, Ji Y, **Pan Q**, Baloch Z.

    The impact of COVID-19 pandemic outbreak on education and mental health of Chinese children aged 7-15 years: an online survey. ***BMC Pediatr***. 2021 Feb 24;21(1):95. (IF: **2.1**)

43. Rajpoot S, Ohishi T, Kumar A, **Pan Q**, Banerjee S, Zhang KYJ, Baig MS.

    A Novel Therapeutic Peptide Blocks SARS-CoV-2 Spike Protein Binding with Host Cell ACE2 Receptor. ***Drugs R D***. 2021 Sep;21(3):273-283. (IF: **2.6**)

44. Li Y, Miao Z, Li P, Zhang R, Kainov DE, Ma Z, de Man RA, Peppelenbosch MP, **Pan Q***.

    Ivermectin effectively inhibits hepatitis E virus replication, requiring the host nuclear transport protein importin α1. ***Arch Virol***. 2021 Jul;166(7):2005-2010. (IF: **2.6**)

45. Ma XX, Ji Y, Jin L, Baloch Z, Zhang DR, Wang Y, **Pan Q***, Ma Z*.

    Prevalence and clinical features of hepatitis E virus infection in pregnant women: A large cohort study in Inner Mongolia, China. ***Clin Res Hepatol Gastroenterol***. 2021 Jul;45(4):101536. (IF: **2.9**)

46. Miao Z, Li Y, Yu P, Yu B, Peppelenbosch MP, **Pan Q***.

    The dynamics of hepatitis delta virus prevalence and its potential association with hepatitis B virus vaccination. ***Clin Res Hepatol Gastroenterol***. 2021 May;45(3):101677. (IF: **2.9**)

**2020**

47. Ji Y, Ma Z, Peppelenbosch MP, **Pan Q***.

    Potential association between COVID-19 mortality and health-care resource availability. ***Lancet Glob Health***. 2020 Apr;8(4):e480. (IF: **26.8**; top**10%**)

48. Cao W, Li M, Liu J, Zhang S, Noordam L, Verstegen MMA, Wang L, Ma B, Li S, Wang W, Bolkestein M, Doukas M, Chen K, Ma Z, Bruno M, Sprengers D, Kwekkeboom J, J W van der Laan L, Smits R, Peppelenbosch MP, **Pan Q***.

    LGR5 marks targetable tumor-initiating cells in mouse liver cancer. ***Nat Commun***. 2020 Apr 23;11(1):1961. (IF: **14.9**; top**10%**)

49. Ma Z, Li P, Ji Y, Ikram A, **Pan Q***.

    Cross-reactivity towards SARS-CoV-2: the potential role of low-pathogenic human coronaviruses. ***Lancet Microbe*** 1(4), e151.

50. Miao Z, **Pan Q***.
    Revisiting the estimation of hepatitis D global prevalence. ***J Hepatol***. 2020 Nov;73(5):1279-1280. (IF: **25.1**; top**10%**)

51. Ma Z, Li P, Ikram A, **Pan Q***.

    Does Cross-neutralization of SARS-CoV-2 Only Relate to High Pathogenic Coronaviruses? ***Trends Immunol***. 2020 Oct;41(10):851-853. (IF: **16.7**; top**10%**)

52. Ma Z, Liu J, **Pan Q***.

    Overwhelming COVID-19 Clinical Trials: Call for Prospective Meta-Analyses. ***Trends Pharmacol Sci***. 2020 Aug;41(8):501-503. (IF: **14.8**; top**10%**)

53. Chen S, Li P, Wang Y, Yin Y, de Ruiter PE, Verstegen MMA, Peppelenbosch MP, van der Laan LJW, **Pan Q***.

    Rotavirus Infection and Cytopathogenesis in Human Biliary Organoids Potentially Recapitulate Biliary Atresia Development. ***mBio***. 2020 Aug 25;11(4):e01968-20. (IF: **7.9**; **Q1**)

54. Hartl L, Duitman J, Aberson HL, Chen K, Dijk F, Roelofs JJTH, Dings MPG, Hooijer GKJ, Hernanda PY, **Pan Q**, Busch OR, Besselink MGH, Boerman T, Peppelenbosch MP, Bijlsma MF, Spek CA.

CCAAT/Enhancer-Binding Protein Delta (C/EBPδ): A Previously Unrecognized Tumor Suppressor that Limits the Oncogenic Potential of Pancreatic Ductal Adenocarcinoma Cells. ***Cancers*** (Basel). 2020 Sep 7;12(9):2546. (IF: **6.6**; **Q1**)

55. Li M, Wang L, Wang Y, Zhang S, Zhou G, Lieshout R, Ma B, Liu J, Qu C, Verstegen MMA, Sprengers D, Kwekkeboom J, van der Laan LJW, Cao W, Peppelenbosch MP, **Pan Q***.

    Mitochondrial Fusion Via OPA1 and MFN1 Supports Liver Tumor Cell Metabolism and Growth. ***Cells***. 2020 Jan 4;9(1):121. (IF: **6.6**)

56. Li Y, Li P, Li Y, Zhang R, Yu P, Ma Z, Kainov DE, de Man RA, Peppelenbosch MP, **Pan Q***.

    Drug screening identified gemcitabine inhibiting hepatitis E virus by inducing interferon-like response via activation of STAT1 phosphorylation. ***Antiviral Res***. 2020 Dec;184:104967. (IF: **6**; **Q1**)

57. Li Y, Yu P, Qu C, Li P, Li Y, Ma Z, Wang W, de Man RA, Peppelenbosch MP, **Pan Q***.

    MDA5 against enteric viruses through induction of interferon-like response partially via the JAK-STAT cascade. ***Antiviral Res***. 2020 Apr;176:104743. (IF: **6**; **Q1**)

58. Yu P, Li Y, Li Y, Miao Z, Wang Y, Peppelenbosch MP, **Pan Q***.

    Murine norovirus replicase augments RIG-I-like receptors-mediated antiviral interferon response. ***Antiviral Res***. 2020 Oct;182:104877. (IF: **6**; **Q1**)

59. Chen S, Wang Y, Li P, Yin Y, Bijvelds MJ, de Jonge HR, Peppelenbosch MP, Kainov DE, **Pan Q***.

    Drug screening identifies gemcitabine inhibiting rotavirus through alteration of pyrimidine nucleotide synthesis pathway. ***Antiviral Res***. 2020 Aug;180:104823. (IF: **6**; **Q1**)

60. Li P, Liu J, Li Y, Su J, Ma Z, Bramer WM, Cao W, de Man RA, Peppelenbosch MP, **Pan Q***.

    The global epidemiology of hepatitis E virus infection: A systematic review and meta-analysis. ***Liver Int***. 2020 Jul;40(7):1516-1528. (IF: **5.8**)

61. Miao Z, Zhang S, Ou X, Li S, Ma Z, Wang W, Peppelenbosch MP, Liu J, **Pan Q***.

    Estimating the Global Prevalence, Disease Progression, and Clinical Outcome of Hepatitis Delta Virus Infection. ***J Infect Dis***. 2020 Apr 27;221(10):1677-1687. (IF: **5.2**; **Q1**)

62. Li P, Liu J, Ma Z, Bramer WM, Peppelenbosch MP, **Pan Q***.

    Estimating Global Epidemiology of Low-Pathogenic Human Coronaviruses in Relation to the COVID-19 Context. ***J Infect Dis***. 2020 Jul 23;222(4):695-696. (IF: **5.2**; **Q1**)

63. Yu P, Li Y, Li Y, Miao Z, Peppelenbosch MP, **Pan Q***.

    Guanylate-binding protein 2 orchestrates innate immune responses against murine norovirus and is antagonized by the viral protein NS7. ***J Biol Chem***. 2020 Jun 5;295(23):8036-8047. (IF: **5.2**)

64. Wang Y, Liu H, Jiang Y, **Pan Q***, Zhao J.

    Poor Outcomes of Acute Hepatitis E in Patients With Cirrhotic Liver Diseases Regardless of Etiology. ***Open Forum Infect Dis***. 2020 Mar 26;7(4):ofaa107. (IF: **3.8**)

65. Ou X, Ma B, Zhang R, Miao Z, Cheng A, Peppelenbosch MP, **Pan Q***.

    A simplified qPCR method revealing tRNAome remodeling upon infection by genotype 3 hepatitis E virus. ***FEBS Lett***. 2020 Jun;594(12):2005-2015. (IF: **4.1**)

66. Baloch Z, Ma Z, Ji Y, Ghanbari M, **Pan Q**, Aljabr W.

    Unique challenges to control the spread of COVID-19 in the Middle East. ***J Infect Public Health***. 2020 Sep;13(9):1247-1250. (IF: **3.7**)

67. Yu P, Li Y, Wang Y, Peppelenbosch MP, **Pan Q***.

    Lipopolysaccharide restricts murine norovirus infection in macrophages mainly through NF-kB and JAK-STAT signaling pathway. ***Virology***. 2020 Jul;546:109-121. (IF: **3.6**)

68. Ou X, Peng W, Yang Z, Cao J, Wang M, Peppelenbosch MP, **Pan Q**, Cheng A.

    Evolutionarily missing and conserved tRNA genes in human and avian. ***Infect Genet Evol***. 2020 Nov;85:104460. (IF: **3.3**)

69. Wang Y, Liu S, **Pan Q**, Zhao J.

    Chronic hepatitis E in an immunocompetent patient. ***Clin Res Hepatol Gastroenterol***. 2020 Jun;44(3):e66-e68. (IF: **2.9**)

70. Yu P, Wang Y, Li Y, Li Y, Miao Z, Peppelenbosch MP, **Pan Q***.

    2'-Fluoro-2'-deoxycytidine inhibits murine norovirus replication and synergizes MPA, ribavirin and T705. ***Arch Virol***. 2020 Nov;165(11):2605-2613. (IF: **2.6**)

71. Li Y, Qu C, Spee B, Zhang R, Penning LC, de Man RA, Peppelenbosch MP, Fieten H, **Pan Q***.

    Hepatitis E virus seroprevalence in pets in the Netherlands and the permissiveness of canine liver cells to the infection. ***Ir Vet J***. 2020 Apr 2;73:6. (IF: **2.1**)

72. Zhang K, Wang XW, Liu H, Ji YP, **Pan QW**, Wei YM, Ma M.

    Mathematical analysis of a human papillomavirus transmission model with vaccination and screening. ***Math Biosci Eng***. 2020 Aug 12;17(5):5449-5476. (IF: **2.1**)

**2019**

73. Kamar N, **Pan Q***.

    No Clear Evidence for an Effect of Sofosbuvir Against Hepatitis E Virus in Organ Transplant Patients. ***Hepatology***. 2019 Apr;69(4):1846-1847. (IF: **17.4**; top**10%**)

74. Chen K, Ma J, Jia X, Ai W, Ma Z, **Pan Q***.

    Advancing the understanding of NAFLD to hepatocellular carcinoma development: From experimental models to humans. ***Biochim Biophys Acta Rev Cancer***. 2019 Jan;1871(1):117-125. (IF: **10.7**; top**10%**)

75. Ou X, Cao J, Cheng A, Peppelenbosch MP, **Pan Q***.

    Errors in translational decoding: tRNA wobbling or misincorporation? ***PLoS Genet***. 2019 Mar 28;15(3):e1008017. (IF: **5.9**; **Q1**)

76. van Beek AA, Zhou G, Doukas M, Boor PPC, Noordam L, Mancham S, Campos Carrascosa L, van der Heide-Mulder M, Polak WG, Ijzermans JNM, **Pan Q**, Heirman C, Mahne A, Bucktrout SL, Bruno MJ, Sprengers D, Kwekkeboom J.

    GITR ligation enhances functionality of tumor-infiltrating T cells in hepatocellular carcinoma. ***Int J Cancer***. 2019 Aug 15;145(4):1111-1124. (IF: **7.4**; **Q1**)

77. Qu C, Zhang S, Li Y, Wang Y, Peppelenbosch MP, **Pan Q***.

    Mitochondria in the biology, pathogenesis, and treatment of hepatitis virus infections. ***Rev Med Virol***. 2019 Sep;29(5):e2075. (IF: **7**; **Q1**)

78. Zhou X, Yang J, Zhang Z, Zhang L, Lie L, Zhu B, Xu L, Gao Y, Du X, Huang Y, Wang R, Liu H, Li Y, Hu S, Zhou C, Wen Q, **Pan Q**, Ma L.

    Interferon regulatory factor 1 eliminates mycobacteria by suppressing p70 S6 kinase via mechanistic target of rapamycin signaling. ***J Infect***. 2019 Sep;79(3):262-276. (IF: **6.1**)

79. Chen S, Ding S, Yin Y, Xu L, Li P, Peppelenbosch MP, **Pan Q**, Wang W.

    Suppression of pyrimidine biosynthesis by targeting DHODH enzyme robustly inhibits rotavirus replication. ***Antiviral Res***. 2019 Jul;167:35-44. (IF: **6**; **Q1**)

80. Qu C, Li Y, Li Y, Yu P, Li P, Donkers JM, van de Graaf SFJ, de Man RA, Peppelenbosch MP, **Pan Q***.

    FDA-drug screening identifies deptropine inhibiting hepatitis E virus involving the NF-κB-RIPK1-caspase axis. ***Antiviral Res***. 2019 Oct;170:104588. (IF: **6**; **Q1**)

81. Wang W, Li S, Liu P, Sideras K, van de Werken HJG, van der Heide M, Cao W, Lavrijsen M, Peppelenbosch MP, Bruno M, **Pan Q**, Smits R.

    Oncogenic STRAP Supports Hepatocellular Carcinoma Growth by Enhancing Wnt/β-Catenin Signaling. ***Mol Cancer Res***. 2019 Feb;17(2):521-531. (IF: **5.9**)

82. Chen S, Feng C, Fang Y, Zhou X, Xu L, Wang W, Kong X, P Peppelenbosch M, **Pan Q**, Yin Y.

    The Eukaryotic Translation Initiation Factor 4F Complex Restricts Rotavirus Infection via Regulating the Expression of IRF1 and IRF7. ***Int J Mol Sci***. 2019 Mar 29;20(7):1580. (IF: **5.9**; **Q1**)

83. Wang Y, Liu H, Liu S, Yang C, Jiang Y, Wang S, Liu A, Peppelenbosch MP, Kamar N, **Pan Q***, Zhao J*.

    Incidence, predictors and prognosis of genotype 4 hepatitis E related liver failure: A tertiary nested case-control study. ***Liver Int***. 2019 Dec;39(12):2291-2300. (IF: **5.8**)

84. Ji Y, Ma XX, Li Z, Peppelenbosch MP, Ma Z, **Pan Q***.

    The Burden of Human Papillomavirus and Chlamydia trachomatis Coinfection in Women: A Large

Cohort Study in Inner Mongolia, China. ***J Infect Dis***. 2019 Jan 7;219(2):206-214. (IF: **5.2**; **Q1**)

85. Ma B, Chen K, Liu P, Li M, Liu J, Sideras K, Sprengers D, Biermann K, Wang W, IJzermans JNM, Cao W, Kwekkeboom J, Peppelenbosch MP, **Pan Q***.

    Dichotomal functions of phosphorylated and unphosphorylated STAT1 in hepatocellular carcinoma. ***J Mol Med***. 2019 Jan;97(1):77-88. (IF: **4.6**)

86. Liu P, Cao W, Ma B, Li M, Chen K, Sideras K, Duitman JW, Sprengers D, Khe Tran TC, Ijzermans JNM, Biermann K, Verheij J, Spek CA, Kwekkeboom J, **Pan Q**, Peppelenbosch MP.

    Action and clinical significance of CCAAT/enhancer-binding protein delta in hepatocellular carcinoma. ***Carcinogenesis***. 2019 Mar 12;40(1):155-163. (IF: **4.9**)

87. Cao W, Liu J, Wang L, Li M, Verstegen MMA, Yin Y, Ma B, Chen K, Bolkestein M, Sprengers D, van der Laan LJW, Doukas M, Kwekkeboom J, Smits R, Peppelenbosch MP, **Pan Q***.

    Modeling liver cancer and therapy responsiveness using organoids derived from primary mouse liver tumors. ***Carcinogenesis***. 2019 Mar 12;40(1):145-154. (IF: **4.9**)

88. Chen K, Sheng J, Ma B, Cao W, Hernanda PY, Liu J, Boor PPC, Tjon ASW, Felczak K, Sprengers D, Pankiewicz KW, Metselaar HJ, Ma Z, Kwekkeboom J, Peppelenbosch MP, **Pan Q***.

    Suppression of Hepatocellular Carcinoma by Mycophenolic Acid in Experimental Models and in Patients. ***Transplantation***. 2019 May;103(5):929-937. (IF: **4.9**)

89. Sideras K, de Man RA, Harrington SM, Polak WG, Zhou G, Schutz HM, Pedroza-Gonzalez A, Biermann K, Mancham S, Hansen BE, Bart Takkenberg R, van Vuuren AJ, **Pan Q**, Ijzermans JNM, Sleijfer S, Sprengers D, Dong H, Kwekkeboom J, Bruno MJ.

    Circulating levels of PD-L1 and Galectin-9 are associated with patient survival in surgically treated Hepatocellular Carcinoma independent of their intra-tumoral expression levels. ***Sci Rep***. 2019 Jul 23;9(1):10677. (IF: **4.4**; **Q1**)

90. Ghanbari M, Munshi ST, Ma B, Lendemeijer B, Bansal S, Adams HH, Wang W, Goth K, Slump DE, van den Hout MCGN, van IJcken WFJ, Bellusci S, **Pan Q**, Erkeland SJ, de Vrij FMS, Kushner SA, Ikram MA.

    A functional variant in the miR-142 promoter modulating its expression and conferring risk of Alzheimer disease. ***Hum Mutat***. 2019 Nov;40(11):2131-2145. (IF: **4.9**; **Q1**)

91. Miao Z, Zhang S, Ma Z, Hakim MS, Wang W, Peppelenbosch MP, **Pan Q***.

    Recombinant identification, molecular classification and proposed reference genomes for hepatitis delta virus. ***J Viral Hepat***. 2019 Jan;26(1):183-190. (IF: **3.7**)

92. Li Y, Qu C, Yu P, Ou X, **Pan Q***, Wang W.

    The Interplay between Host Innate Immunity and Hepatitis E Virus. ***Viruses***. 2019 Jun 11;11(6):541. (IF: **5**)

93. Yang Q, Liu J, Ma W, Wang J, Li F, Bramer WM, Peppelenbosch MP, **Pan Q***.

    Efficacy of Different Endoscopic Stents in the Management of Postoperative Biliary Strictures: A Systematic Review and Meta-analysis. ***J Clin Gastroenterol***. 2019 Jul;53(6):418-426. (IF: **3.1**)

94. Nirwati H, Donato CM, Ikram A, Aman AT, Wibawa T, Kirkwood CD, Soenarto Y, **Pan Q**, Hakim MS.

    Phylogenetic and immunoinformatic analysis of VP4, VP7, and NSP4 genes of rotavirus strains circulating in children with acute gastroenteritis in Indonesia. ***J Med Virol***. 2019 Oct;91(10):1776-1787. (IF: **2.3**)

95. Ji Y, Zhao C, Ma XX, Peppelenbosch MP, Ma Z, **Pan Q***.

    Outcome of a screening program for the prevention of neonatal early-onset group B Streptococcus infection: a population-based cohort study in Inner Mongolia, China. ***J Med Microbiol***. 2019 May;68(5):803-811. (IF: **2.5**)

96. Nirwati H, Donato CM, Mawarti Y, Mulyani NS, Ikram A, Aman AT, Peppelenbosch MP, Soenarto Y, **Pan Q**, Hakim MS.

    Norovirus and rotavirus infections in children less than five years of age hospitalized with acute gastroenteritis in Indonesia. ***Arch Virol***. 2019 Jun;164(6):1515-1525. (IF: **2.6**)

97. Liu J, Ma B, Cao W, Li M, Bramer WM, Peppelenbosch MP, **Pan Q***.

    Direct-acting antiviral agents for liver transplant recipients with recurrent genotype 1 hepatitis C virus

infection: Systematic review and meta-analysis. ***Transpl Infect Dis***. 2019 Apr;21(2):e13047. (IF: **2.2**)

98. Liu J, Cao W, Ma B, Li M, Peppelenbosch MP, **Pan Q***.

    Sofosbuvir directly promotes the clonogenic capability of human hepatocellular carcinoma cells. ***Clin Res Hepatol Gastroenterol***. 2019 Oct;43(5):e79-e81. (IF: **2.9**)

99. Wu J, Zhang X, Liu H, Guo N, **Pan Q**, Wang Y.

    RDW, NLR and RLR in predicting liver failure and prognosis in patients with hepatitis E virus infection. ***Clin Biochem***. 2019 Jan;63:24-31. (IF: 2.6)

100. Zhou JH, Li XR, Lan X, Han SY, Wang YN, Hu Y, **Pan Q***.

    The genetic divergences of codon usage shed new lights on transmission of hepatitis E virus from swine to human. ***Infect Genet Evol***. 2019 Mar;68:23-29. (IF: **3.3**)

101. Ji Y, Ikram A, Ma Z, Peppelenbosch MP, **Pan Q***.

    Co-occurrence of heterozygous mutations in COL1A1 and SERPINF1 in a high-risk pregnancy complicated by osteogenesis imperfecta. ***J Genet***. 2019 Jun;98(2):51. (IF: **1.2**)

**2018**

102. Wang Y, Chen G, **Pan Q**, Zhao J.

    Chronic Hepatitis E in a Renal Transplant Recipient: The First Report of Genotype 4 Hepatitis E Virus Caused Chronic Infection in Organ Recipient. ***Gastroenterology***. 2018 Feb 9. (IF: **22.7**; top**10%**)

103. Wang W, Wang Y, Qu C, Wang S, Zhou J, Cao W, Xu L, Ma B, Hakim MS, Yin Y, Li T, Peppelenbosch MP, Zhao J, **Pan Q***.

    The RNA genome of hepatitis E virus robustly triggers an antiviral interferon response. ***Hepatology***. 2018 Jun;67(6):2096-2112. (IF: **17.4**; top**10%**)

104. Xiao-xia Ma, Zhongren Ma, **Qiuwei Pan***.

    The Challenges of Long-Term Transcriptional Gene Silencing by RNA Viruses. ***Trends in Biochemical Sciences***. 2018 (IF: **13.8**; top**10%**)

105. Wang Y, Wang S, Wu J, Jiang Y, Zhang H, Li S, Liu H, Yang C, Tang H, Guo N, Peppelenbosch MP, Wei L, **Pan Q***, Zhao J.

    Hepatitis E virus infection in acute non-traumatic neuropathy: A large prospective case-control study in China. ***EBioMedicine***. 2018 Oct;36:122-130. (IF: **8.1**; **Q1**)

106. Hakim MS, Ikram A, Zhou J, Wang W, Peppelenbosch MP, **Pan Q***.

    Immunity against hepatitis E virus infection: Implications for therapy and vaccine development. ***Rev Med Virol***. 2018 Mar;28(2). (IF: **7**; **Q1**)

107. Yin Y, Chen S, Hakim MS, Wang W, Xu L, Dang W, Qu C, Verhaar AP, Su J, Fuhler GM, Peppelenbosch MP, **Pan Q*.**

    6-Thioguanine inhibits rotavirus replication through suppression of Rac1 GDP/GTP cycling. ***Antiviral Res.*** 2018 Aug;156:92-101. (IF: **6**; **Q1**)

108. Dang W, Xu L, Yin Y, Chen S, Wang W, Hakim MS, Chang KO, Peppelenbosch MP, **Pan Q***.

    IRF-1, RIG-I and MDA5 display potent antiviral activities against norovirus coordinately induced by different types of interferons. ***Antiviral Res***. 2018 Jul;155:48-59. (IF: **6**; **Q1**)

109. Ikram A, Hakim MS, Zhou JH, Wang W, Peppelenbosch MP, **Pan Q***.

    Genotype-specific acquisition, evolution and adaptation of characteristic mutations in hepatitis E virus. ***Virulence***. 2018 Jan 1;9(1):121-132. (IF: **5.9**; **Q1**)

110. Yin Y, Dang W, Zhou X, Xu L, Wang W, Cao W, Chen S, Su J, Cai X, Xiao S, Peppelenbosch MP, **Pan Q***.

    PI3K-Akt-mTOR axis sustains rotavirus infection via the 4E-BP1 mediated autophagy pathway and represents an antiviral target. ***Virulence***. 2018 Jan 1;9(1):83-98. (IF: **5.9**; **Q1**)

111. Qu C, Zhang S, Wang W, Li M, Wang Y, van der Heijde-Mulder M, Shokrollahi E, Hakim MS, Raat NJH, Peppelenbosch MP, **Pan Q***.

    Mitochondrial electron transport chain complex III sustains hepatitis E virus replication and represents an antiviral target. ***FASEB J***. 2018 Aug 2:fj201800620R. (IF: **5.2**; **Q1**)

112. Dang W, Xu L, Ma B, Chen S, Yin Y, Chang KO, Peppelenbosch MP, **Pan Q***.

Nitazoxanide Inhibits Human Norovirus Replication and Synergizes with Ribavirin by Activation of Cellular Antiviral Response. ***Antimicrob Agents Chemother***. 2018 Aug 13. pii: AAC.00707-18. (IF: **5.2**, **Q1**)

113. Ou X, Wang M, Mao S, Cao J, Cheng A, Zhu D, Chen S, Jia R, Liu M, Yang Q, Wu Y, Zhao X, Zhang S, Liu Y, Yu Y, Zhang L, Chen X, Peppelenbosch MP, **Pan Q***.

    Incompatible Translation Drives a Convergent Evolution and Viral Attenuation During the Development of Live Attenuated Vaccine. ***Front Cell Infect Microbiol***. 2018 Jul 18;8:249. (IF: **5.3**; **Q1**)

114. Hakim MS, Chen S, Ding S, Yin Y, Ikram A, Ma XX, Wang W, Peppelenbosch MP, **Pan Q***.

    Basal interferon signaling and therapeutic use of interferons in controlling rotavirus infection in human intestinal cells and organoids. ***Sci Rep***. 2018 May 29;8(1):8341. (IF: **4.4**; **Q1**)

115. Baig MS, Roy A, Saqib U, Rajpoot S, Srivastava M, Naim A, Liu D, Saluja R, Faisal SM, **Pan Q**, Turkowski K, Darwhekar GN, Savai R.

    Repurposing Thioridazine (TDZ) as an anti-inflammatory agent. ***Sci Rep***. 2018 Aug 20;8(1):12471. (IF: **4.4**; **Q1**)

116. Yang Q, Wang J, Liu F, Ma W, Hu H, Ran C, Li F, **Pan Q***.

    A Novel Rabbit Model for Benign Biliary Stricture Formation and the Effects of Medication Infusions on Stricture Formation. ***Dig Dis Sci***. 2018 May 16. (IF: **3.2**)

117. Yang Q, Wu Z, Liu F, Wang J, Ma W, Hu H, Li F, **Pan Q***.

    Effective Treatment of Chronic Proliferative Cholangitis by Local Gentamicin Infusion in Rabbits. ***Biomed Res Int***. 2018 Jul 24;2018:6751952. (IF: **3.4**)

118. Hakim MS, Ding S, Chen S, Yin Y, Su J, van der Woude CJ, Fuhler GM, Peppelenbosch MP, **Pan Q**, Wang W.

    TNF-α exerts potent anti-rotavirus effects via the activation of classical NF-κB pathway. ***Virus Res.*** 2018 May 31;253:28-37. (IF: **3.3**)

119. Zhang S, Qu C, Wang Y, Wang W, Ma Z, Peppelenbosch MP, **Pan Q***.

    Conservation and variation of the hepatitis E virus ORF2 capsid protein. ***Gene***. 2018 Oct 30;675:157-164. (IF: **3.9**)

120. Zhou S, Ren L, Xia X, Miao Z, Huang F, Li Y, Zhu M, Xie Z, Xu Y, Qian Y, **Pan Q***, Wang K*.

    Hepatitis E virus infection in HIV-infected patients: a large cohort study in Yunnan province, China. ***J Med Virol***. 2018 Feb 19. (IF: **2.3**)

121. Chang QY, Guo FC, Li XR, Zhou JH, Cai X, **Pan Q**, Ma XX.

    The IMPDH inhibitors, ribavirin and mycophenolic acid, inhibit peste des petits ruminants virus infection. ***Vet Res Commun***. 2018 Aug 9. doi: 10.1007/s11259-018-9733-1. (IF: **2.5**; **Q1**)

122. Hakim MS, Nirwati H, Aman AT, Soenarto Y, **Pan Q***.

    Significance of continuous rotavirus and norovirus surveillance in Indonesia. ***World J Pediatr***. 2018 Feb 14. (IF: **2.8**)

**2017**

123. Cao W, Chen K, Bolkestein M, Yin Y, Verstegen MMA, Bijvelds MJC, Wang W, Tuysuz N, Ten Berge D, Sprengers D, Metselaar HJ, van der Laan LJW, Kwekkeboom J, Smits R, Peppelenbosch MP, **Pan Q***.

    Dynamics of Proliferative and Quiescent Stem Cells in Liver Homeostasis and Injury. ***Gastroenterology***. 2017 Jul 14. pii: S0016-5085(17)35907-3. (IF: **22.7**; top**10%**)

124. Wang W, Yin Y, Xu L, Su J, Huang F, Wang Y, Boor PPC, Chen K, Wang W, Cao W, Zhou X, Liu P, van der Laan LJW, Kwekkeboom J, Peppelenbosch MP, **Pan Q***.

    Unphosphorylated ISGF3 drives constitutive expression of interferon-stimulated genes to protect against viral infections. ***Science Signaling***. 2017 Apr 25;10(476). pii: eaah4248. (IF: **8.2**; **Q1**)

125. Nano J, Ghanbari M, Wang W, de Vries PS, Dhana K, Muka T, Uitterlinden AG, van Meurs JBJ, Hofman A; BIOS consortium, Franco OH, **Pan Q**, Darwish Murad S, Dehghan A.

    Epigenome-wide Association Study Identifies Methylation Sites Associated With Liver Enzymes and Hepatic Steatosis. ***Gastroenterology.*** 2017 Jun 14. pii: S0016-5085(17)35737-2. (IF: **22.7**; top**10%**)

126. Zhou G, Sprengers D, Boor PPC, Doukas M, Schutz H, Mancham S, Pedroza-Gonzalez A, Polak WG, de Jonge J, Gaspersz M, Dong H, Thielemans K, **Pan Q**, IJzermans JNM, Bruno MJ, Kwekkeboom J.

Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-infiltrating T cells in Hepatocellular Carcinomas. ***Gastroenterology***. 2017 Oct;153(4):1107-1119.e10. (IF: **22.7**; top**10%**)

127. Xu L, Wang W, Li Y, Zhou X, Yin Y, Wang Y, de Man RA, van der Laan LJ, Huang F, Kamar N, Peppelenbosch MP, **Pan Q***.

RIG-I Is A Key Antiviral Interferon-Stimulated Gene Against Hepatitis E Virus Dispensable Of Interferon Production. ***Hepatology***. 2017 Feb 13. doi: 10.1002/hep.29105. (IF: **17.4**; top**10%**)

128. Kamar N, Wang W, Dalton HR, **Pan Q***.

Direct-acting antiviral therapy for hepatitis E virus? ***The Lancet Gastroenterology & Hepatology***. 2017, 2(3): 154-155(IF: **18.9**; top**10%**)

129. Wang W, Xu L, Su J, Peppelenbosch MP, **Pan Q***.

Transcriptional Regulation of Antiviral Interferon-Stimulated Genes. ***Trends Microbiol***. 2017 Jul;25(7):573-584. (IF: **17.1**; top**10%**)

130. Xu L, Wang W, Peppelenbosch MP, **Pan Q***.

Noncanonical Antiviral Mechanisms of ISGs: Dispensability of Inducible Interferons. ***Trends Immunol.*** 2017 Jan;38(1):1-2. (IF: **16.7**; top**10%**)

131. Ma B, **Pan Q**, Peppelenbosch MP.

Genetically engineered bacteria for treating human disease. ***Trends Pharmacol Sci***. 2017, Sep;38(9):763-764. (IF: **14.8**; top**10%**)

132. Li M, **Pan Q**, Peppelenbosch MP.

Should Nivolumab-Induced Colitis Be Treated by Infliximab? ***Clin Gastroenterol Hepatol.*** 2017 Oct;15(10):1637. (IF: **11.4**; top**10%**)

133. Wang W, Wang Y, Debing Y, Zhou X, Yin Y, Xu L, Herrera Carrillo E, Brandsma JH, Poot RA, Berkhout B, Neyts J, Peppelenbosch MP, **Pan Q***.

Biological or pharmacological activation of protein kinase C alpha constrains hepatitis E virus replication. ***Antiviral Res***. 2017 Apr;140:1-12. (IF: **6**; **Q1**)

134. Hakim MS, Wang W, Bramer WM, Geng J, Huang F, de Man RA, Peppelenbosch MP, **Pan Q***.

The Global Burden of Hepatitis E Outbreaks. ***Liver Int***. 2017 Jan;37(1):19-31. (IF: **5.8**)

135. Chen K, Ma B, Peppelenbosch MP, **Pan Q***.

Cytoplasmic rods and rings in mycophenolic acid treatment. ***Liver Int***. 2017 37(11):1742-1743. (IF: **5.8**)

136. Geng J, Cao Z, Ma X, Shi Y, Wang Y, **Pan Q***.

Mushroom poisoning: an overlooked cause of acute liver injury in China. ***Liver Int***. 2017 Mar;37(3):468-469. (IF: **5.8**)

137. Zhou X, Huang F, Xu L, Lin Z, de Vrij FM, Ayo-Martin AC, van der Kroeg M, Zhao M, Yin Y, Wang W, Cao W, Wang Y, Kushner SA, Peron JM, Alric L, de Man RA, Jacobs BC, van Eijk JJ, Aronica EM, Sprengers D, Metselaar HJ, de Zeeuw CI, Dalton HR, Kamar N, Peppelenbosch MP, **Pan Q***.

Hepatitis E virus infects neurons and brains. ***J Infect Dis***. 2017 Apr 15;215(8):1197-1206. (IF: **5.2**; **Q1**)

138. Dang W, Yin Y, Peppelenbosch MP, **Pan Q***.

Opposing Effects of Nitazoxanide on Murine and Human Norovirus. ***J Infect Dis***. 2017 Sep 15;216(6):780-782. (IF: **5.2**; **Q1**)

139. Li J, Hansen BE, Peppelenbosch MP, De Man RA, **Pan Q**, Sprengers D.

Factors associated with ethnical disparity in overall survival for patients with hepatocellular carcinoma. ***Oncotarget***. 2017 Jan 20. doi: 10.18632/oncotarget.14771.

140. Dang W, Yin Y, Wang Y, Wang W, Su J, Sprengers D, van der Laan LJW, Felczak K, Pankiewicz KW, Chang KO, Koopmans MPG, Metselaar HJ, Peppelenbosch MP, **Pan Q***.

Inhibition of Calcineurin or IMP Dehydrogenase Exerts Moderate to Potent Antiviral Activity against Norovirus Replication. ***Antimicrob Agents Chemother.*** 2017 Oct 24;61(11). (IF: **5.2**, **Q1**)

141. Ren L, Li J, Zhou S, Xia X, Xie Z, Liu P, Xu Y, Qian Y, Zhang H, Ma L, **Pan Q**, Wang K.

Prognosis of HIV Patients Receiving Antiretroviral Therapy According to CD4 Counts: A Long-term Follow-up study in Yunnan, China. ***Sci Rep***. 2017 Aug 29;7(1):9595. (IF: **4.4**; **Q1**)

142. Li J, Verhaar AP, **Pan Q**, de Knegt RJ, Peppelenbosch MP.

    Serum levels of caspase-cleaved cytokeratin 18 (CK18-Asp396) predict severity of liver disease in chronic hepatitis B. ***Clin Exp Gastroenterol***. 2017 Aug 11;10:203-209.

143. Wang XH, Ji YP, Li J, Dong H, Zhu B, Zhou Y, Wang J, Zhou XY, Wang Y, Peppelenbosch MP, **Pan Q**, Ji XP, Liu DJ.

    Prevalence of Human Papillomavirus Infection in Women in the Autonomous Region of Inner Mongolia: a Population-based Study of a Chinese Ethnic Minority. ***J Med Virol***. 2017 Jun 29. doi: 10.1002/jmv.24888. (IF: **2.3**)

144. Naim A, **Pan Q**, Baig MS.

    Matrix Metalloproteinases (MMPs) in Liver Diseases. ***J Clin Exp Hepatol***. 2017 Dec;7(4):367-372.

145. Nirwati H, Hakim MS, Aminah S, Dwija IBNP, **Pan Q**, Aman AT.

    Identification of Rotavirus Strains Causing Diarrhoea in Children under Five Years of Age in Yogyakarta, Indonesia. ***Malays J Med Sci***. 2017;24(2):68–77. (IF: **1.4**)

146. Qu C, Xu L, Yin Y, Peppelenbosch MP, **Pan Q**, Wang W.

    Nucleoside analogue 2'-C-methylcytidine inhibits hepatitis E virus replication but antagonizes ribavirin. ***Arch Virol***. 2017 Jun 16. doi: 10.1007/s00705-017-3444-8. (IF: **2.6**)

**2016**

147. Wang W, Hakim MS, Nair VP, de Ruiter PE, Huang F, Sprengers D, Van Der Laan LJ, Peppelenbosch MP, Surjit M, **Pan Q***.

    Distinct Antiviral Potency of Sofosbuvir against Hepatitis C and E Viruses. ***Gastroenterology***. 2016 Dec;151(6):1251-1253. (IF: **22.7**; top**10%**)

148. Wang W, Peppelenbosch MP, **Pan Q***.

    Targeting viral polymerase for treating hepatitis E infection: how far are we? ***Gastroenterology***. 2016. Jun;150(7):1690. (IF: **22.7**; top**10%**)

149. Huang F, Li Y, Yu W, Jing S, Wang J, Long F, He Z, Yang C, Bi Y, Cao W, Liu C, Hua X, **Pan Q**.

    Excretion of infectious hepatitis E virus into milk in cows imposes high risks of zoonosis. ***Hepatology***. 2016 Aug;64(2):350-9. (IF: **17.4**; top**10%**)

150. Huang F, Yang C, Zhou X, Yu W, **Pan Q***.

    Rhesus macaques persistently infected with hepatitis E shed virus into urine. ***J Hepatol***. 2016 Jun;64(6):1446-7. (IF: **25.1**; top**10%**)

151. Wang W, **Pan Q**, Fuhler GM, Smits R, Peppelenbosch MP.

    Action and function of Wnt/β-catenin signaling in the progression from chronic hepatitis C to hepatocellular carcinoma. ***J Gastroenterol***. 2016 Dec 29. doi: 10.1007/s00535-016-1299-5. (IF: **7.5**; Q1)

152. Yin Y, Wang Y, Dang W, Xu L, Su J, Zhou X, Wang W, Felczak K, van der Laan LJ, Pankiewicz KW, van der Eijk AA, Bijvelds M, Sprengers D, de Jonge H, Koopmans MP, Metselaar HJ, Peppelenbosch MP, **Pan Q***.

    Mycophenolic Acid Potently Inhibits Rotavirus Infection with a High Barrier to Resistance Development. ***Antiviral Res***. 2016 Sep;133:41-9. (IF: **6**; **Q1**)

153. Wang W, Xu L, Liu P, Jairam K, Yin Y, Chen K, Sprengers D, Peppelenbosch MP, **Pan Q**, Smits R.

    Blocking Wnt Secretion Reduces Growth of Hepatocellular Carcinoma Cell Lines Mostly Independent of β-Catenin Signaling. ***Neoplasia***. 2016 Dec;18(12):711-723. (IF: **5.7**)

154. Xu L, Zhou X, Wang W, Wang Y, Yin Y, Laan LJ, Sprengers D, Metselaar HJ, Peppelenbosch MP, **Pan Q***.

    Interferon Regulatory Factor 1 Restricts Hepatitis E Virus Replication by Activating STAT1 to Induce Antiviral Interferon-stimulated Genes. ***FASEB J.*** 2016 Oct;30(10):3352-3367. (IF: **5.2**; **Q1**)

155. Wang Y, Wang W, Xu L, Zhou X, Shokrollahi E, Felczak K, van der Laan LJ, Pankiewicz KW, Sprengers D, Raat NJ, Metselaar HJ, Peppelenbosch MP, **Pan Q***.

    Crosstalk between Nucleotide Synthesis Pathways with Cellular Immunity in Constraining Hepatitis E Virus Replication. ***Antimicrob Agents Chemother***. 2016 Feb 29. pii: AAC.02700-15. (IF: **5.2**, **Q1**)

156. Wang W, Xu L, Brandsma JH, Wang Y, Hakim MS, Zhou X, Yin Y, Fuhler GM, van der Laan LJ, van der Woude CJ, Sprengers D, Metselaar HJ, Smits R, Poot RA, Peppelenbosch MP, **Pan Q***.

Convergent Transcription of Interferon-stimulated Genes by TNF-α and Interferon-α Augments Their Antiviral Activity. ***Sci Rep***. 2016, May 6;6:25482. (IF: **4.4**; **Q1**)

157. Zhou X, Xu L, Wang W, Watashi K, Wang Y, Sprengers D, de Ruiter PE, van der Laan LJ, Metselaar HJ, Kamar N, Peppelenbosch MP, **Pan Q***.

Disparity of basal and therapeutically activated interferon signaling in constraining hepatitis E virus infection. ***J Viral Hepat***. 2016 Apr;23(4):294-304. (IF: **3.7**)

**2015**

158. Cao W, Peppelenbosch MP, **Pan Q***.

Virus-host interactions in HBV-related hepatocellular carcinoma: more to be revealed? ***Gut***. 2015 May;64(5):852-3. (IF: **23.1**; top**10%**)

159. Yin Y, Metselaar HJ, Sprengers D, Peppelenbosch MP, **Pan Q***.

Rotavirus in organ transplantation: drug-virus-host interactions. ***Am J Transplant***. 2015 Mar;15(3):585-93. (IF: **8.1**; top**10%**)

160. Pedroza-Gonzalez A, Zhou G, Singh SP, Boor PP, **Pan Q**, Grunhagen D, de Jonge J, Tran TK, Verhoef C, IJzermans JN, Janssen H, Biermann K, Kwekkeboom J, Sprengers D.

GITR engagement in combination with CTLA-4 blockade completely abrogates immunosuppression mediated by human liver tumor-derived regulatory T cells ex vivo. ***Oncoimmunology***, 015 May 29;4(12):e1051297. (IF: **8.1**; **Q1**)

161. Pedroza-Gonzalez A, Zhou G, Vargas-Mendez E, Boor PP, Mancham S, Verhoef C, Polak WG, Grünhagen D, **Pan Q**, Janssen H, Garcia-Romo GS, Biermann K, Tjwa ET, IJzermans JN, Kwekkeboom J, Sprengers D.

Tumor-infiltrating plasmacytoid dendritic cells promote immunosuppression by Tr1 cells in human liver tumors. ***Oncoimmunology***, 2015 Mar 19;4(6):e1008355. (IF: **8.1**; **Q1**)

162. Sideras K, Bots SJ, Biermann K, Sprengers D, Polak WG, IJzermans JN, de Man RA, **Pan Q**, Sleijfer S, Bruno MJ, Kwekkeboom J.

Tumor antigen expression in hepatocellular carcinoma in a low-endemic western area. ***Br J Cancer*** 2015, 2015 Jun 9;112(12):1911-20. (IF: **7.6**; **Q1**)

163. Chen K, Cao W, Li J, Sprengers D, Hernanda PY, Kong X, Van Der Laan LJ, Man K, Kwekkeboom J, Metselaar HJ, Peppelenbosch MP, **Pan Q***.

Differential Sensitivities of Fast- and Slow-cycling Cancer Cells to Inosine Monophosphate Dehydrogenase 2 Inhibition by Mycophenolic Acid. ***Mol Med***. 2015 Oct 13. doi: 10.2119/molmed.2015.00126. (IF: **6.4**; **Q1**)

164. Yin Y, Bijvelds M, Dang W, Xu L, van der Eijk AA, Knipping K, Tuysuz N, Dekkers JF, Wang Y, de Jonge J, Sprengers D, van der Laan LJ, Beekman JM, Ten Berge D, Metselaar HJ, de Jonge H, Koopmans MP, Peppelenbosch MP, **Pan Q***.

Modeling rotavirus infection and antiviral therapy using primary intestinal organoids. ***Antiviral Res***. 2015, Nov;123:120-31. (IF: **6**; **Q1**)

165. Zhou X, Xu L, Wang Y, Wang W, Sprengers D, Metselaar HJ, Peppelenbosch MP, **Pan Q***.

Requirement of the eukaryotic translation initiation factor 4F complex in hepatitis E virus replication. ***Antiviral Res***. 2015 Oct 23;124:11-19. (IF: **6**; **Q1**)

166. Li J, Hernanda PY, Bramer WM, Peppelenbosch MP, van Luijk J, **Pan Q***.

Anti-tumor effects of metformin in animal models of hepatocellular carcinoma: a systematic review and meta-analysis. ***PLoS One***. 2015 Jun 1;10(6):e0127967. (IF: **3.2**)

167. Xu L, Zhou X, Peppelenbosch MP, **Pan Q***.

Inhibition of hepatitis E virus replication by proteasome inhibitor is nonspecific. ***Arch Virol***. 2015 Feb;160(2):435-9. (IF: **2.6**)

**2014**

168. Wang Y, Zhou X, Debing Y, Chen K, Van Der Laan LJ, Neyts J, Janssen HL, Metselaar HJ, Peppelenbosch MP, **Pan Q***.

Calcineurin Inhibitors Stimulate and Mycophenolic Acid Inhibits Replication of Hepatitis E Virus. ***Gastroenterology***. 2014 Jun;146(7):1775-83. (IF: **22.7**; top**10%**)

169. Zhou X, Wang Y, Metselaar HJ, Janssen HL, Peppelenbosch MP, **Pan Q***.

    Rapamycin and everolimus facilitate hepatitis E virus replication: revealing a basal defense mechanism of PI3K-PKB-mTOR pathway. ***J Hepatol***. 2014 Oct;61(4):746-54. (IF: **25.1**; top**10%**)

170. Hernanda PY, Chen K, Das AM, Sideras K, Wang W, Li J, Cao W, Bots SJ, Kodach LL, de Man RA, Ijzermans JN, Janssen HL, Stubbs AP, Sprengers D, Bruno MJ, Metselaar HJ, Ten Hagen TL, Kwekkeboom J, Peppelenbosch MP, **Pan Q***.

    SMAD4 exerts a tumor-promoting role in hepatocellular carcinoma. ***Oncogene***. 2015 Sep 24;34(39):5055-68. (IF: **9.9**; top**10%**)

171. Hernanda PY, Pedroza-Gonzalez A, Sprengers D, Peppelenbosch MP, **Pan Q***.

    Multipotent mesenchymal stromal cells in liver cancer: implications for tumor biology and therapy. ***BBA Reviews on Cancer***. 2014 Dec;1846(2):439-45. (IF: **10.7**; top**10%**)

172. Rodriguez R, Rosu-Myles M, Aráuzo-Bravo M, Horrillo A, **Pan Q**, Gonzalez-Rey E, Delgado M, Menendez P.

    Human bone marrow stromal cells lose immunosuppressive and anti-inflammatory properties upon oncogenic transformation. ***Stem Cell Reports***. 2014 Oct 14;3(4):606-19. (IF: **7.8**; **Q1**)

173. Chen K, **Pan Q**, Gao Y, Yang X, Wang S, Peppelenbosch MP, Kong X.

    DMS triggers apoptosis associated with inhibition of SPHK1/NF-κB activation and increase of intracellular Ca2+ concentration in human cancer cells. ***International Journal of Molecular Medicine***. 2014 Jan; 33(1):17-24. (IF: **5.9**; **Q1**)

174. Chen K, Man K, Metselaar HJ, Janssen HL, Peppelenbosch MP, **Pan Q***.

    Rationale of personalized immunosuppressive medication for hepatocellular carcinoma patients after liver transplantation. ***Liver Transplantation***. 2014, 20 (3): 261-269. (IF: **5.8**, **Q1**, **Q1**)

175. Debing Y, Emerson SU, Wang Y, **Pan Q**, Balzarini J, Dallmeier K, Neyts J.

    Interferon-alpha and ribavirin inhibit in vitro hepatitis E virus replication. ***Antimicrobial Agents and Chemotherapy***. 2014 Jan; 58(1):267-73. (IF: **5.2**, **Q1**)

176. Wang Y, Metselaar HJ, Peppelenbosch MP, **Pan Q***.

    Chronic hepatitis E in solid-organ transplantation: the key implications of immunosuppressants. ***Curr Opin Infect Dis***. 2014 Aug;27(4):303-8. (IF: **4.9**)

177. van der Laan LJ, de Ruiter PE, van Gils IM, Fieten H, Spee B, **Pan Q**, Rothuizen J, Penning LC.

    Canine hepacivirus and idiopathic hepatitis in dogs from a Dutch cohort. ***J Viral Hepat***. 2014 Dec;21(12):894-6. (IF: **3.7**)

178. **Pan Q***, Fouraschen SM, de Ruiter PE, Dinjens WN, Kwekkeboom J, Tilanus HW, van der Laan LJ.

    Detection of spontaneous tumorigenic transformation during culture expansion of human mesenchymal stromal cells. ***Experimental Biology and Medicine***. 2014 Jan; 239 (1):105-15. (IF: **2.7**)

179. Hakim MS, Zhou X, Wang Y, Peppelenbosch MP, **Pan Q***.

    Anti-diabetic drugs, insulin and metformin, have no direct interaction with hepatitis C virus infection or anti-viral interferon response. ***AIMS Molecular Science***. 2014, 2: 1-10.

**2013**

180. **Pan Q**[#], Nicholson AM[#], Barr H[#], Harrison LA[#], Wilson GD, Burkert J, Jeffery R, Alison MR, Looijenga L, Lin WR, McDonald SA, Wright NA, Harrison R, Peppelenbosch MP, Jankowski JA.

    The identification of lineage uncommitted, long-lived, label-retaining cells in the normal human esophagus and stomach as well as metaplastic esophagus. ***Gastroenterology***. 2013 Apr;144(4):761-70. (IF: **22.7**; top**10%**)

181. Hall SR, Pedroza-Gonzalez A, **Pan Q**, Tilanus HW, de Jonge J, Wagemaker G, van der Laan LJ.

    Overestimation of Hematopoietic Stem Cell Frequencies in Human Liver Grafts. ***Hepatology***. 2013 Jun;57(6):2547-9. (IF: **17.4**; top**10%**)

182. Ramakrishnaiah V, Thumann C, Fofana I, Habersetzer F, **Pan Q**, de Ruiter PE, Willemsen R, Demmers JA, Stalin Raj V, Jenster G, Kwekkeboom J, Tilanus HW, Haagmans BL, Baumert TF, van der Laan LJ.

    Exosome-mediated transmission of hepatitis C virus between Huh7.5 cells. ***PNAS***, 2013 Aug 6;110(32):13109-13. (IF: **11.2**; **Q1**)

183. Zhou X, de Man RA, de Knegt RJ, Metselaar HJ, Peppelenbosch MP, **Pan Q***.

    Epidemiology and management of hepatitis E infection in solid organ transplant patients: a comprehensive literature review. ***Reviews in Medical Virology***. 2013 Sep;23(5):295-304. (IF: **7**; **Q1**)

184. Hernanda PY, Pedroza-Gonzalez A, van der Laan LJ, Bröker ME, Hoogduijn MJ, Ijzermans JN, Bruno MJ, Janssen HL, Peppelenbosch MP, **Pan Q***.

    Tumor promotion through the mesenchymal stem cell compartment in human hepatocellular carcinoma. ***Carcinogenesis***. 2013 Oct;34(10):2330-40. (IF: **4.9**)

185. Roemeling-van Rhijn M, de Klein JE, Douben H, **Pan Q**, van der Laan LJW, IJzermans JNM., Betjes MGH., Baan CC, Weimar W, Hoogduijn MJ.

    Aneuploidy in Adipose tissue-derived Mesenchymal Stem Cells and Implications for Clinical Use. ***Cytotherapy*** . 2013 Nov;15(11):1352-61. (IF: **5.4**; **Q1**)

**2012**

186. **Pan Q**, Tilanus HW, Metselaar HJ, Janssen HL, van der Laan LJ.

    Virus-drug interactions-molecular insight into immunosuppression and HCV. ***Nature Reviews Gastroenterology & Hepatology***. 2012 Apr 17;9(6):355-62. (IF: **46.8**; top**10%**)

187. **Pan Q**, Ramakrishnaiah V, Henry S, Fouraschen S, de Ruiter PE, Kwekkeboom J, Tilanus HW, Janssen HL, van der Laan LJ.

    Hepatic cell-to-cell transmission of small silencing RNA extends the therapeutic reach of RNAi again hepatitis C infection. ***Gut***. 2012, 61(9):1330-9. (IF: **23.1**; top**10%**)

188. **Pan Q**, de Ruiter PE, Metselaar HJ, Kwekkeboom J, de Jonge J, Tilanus HW, Janssen HL, van der Laan LJ.

    Mycophenolic acid augments interferon-stimulated gene expression and inhibits hepatitis C virus infection in vitro and in vivo. ***Hepatology***. 2012, 55(6):1673-83. (IF: **17.4**; top**10%**)

189. **Pan Q**, van Vuuren AJ, van der Laan LJ, Peppelenbosch MP, Janssen HL.

    Antiviral or proviral action of mycophenolic acid in hepatitis B infection? ***Hepatology***. 2012, 56(4):1586-7. (IF: **17.4**; top**10%**)

190. **Pan Q**, van der Laan LJ, Janssen HL, Peppelenbosch MP.

    A dynamic perspective of RNAi library development. ***Trends in Biotechnology***. 2012, 0(4):206-15. (IF: **19.5**; top**10%**)

191. Fouraschen SM, **Pan Q**, de Ruiter PE, Farid W, Kazemier G, Kwekkeboom J, Ijzermans JN, Metselaar HJ, Tilanus HW, de Jonge J, van der Laan LJ.

    Secreted factors of human liver-derived mesenchymal stem cells promote liver regeneration early after partial hepatectomy. ***Stem Cells Dev***. 2012, 21(13):2410-9. (IF: **3.3**)

192. Farid WR, **Pan Q**, van der Meer AJ, de Ruiter PE, Ramakrishnaiah V, de Jonge J, Kwekkeboom J, Janssen HL, Metselaar HJ, Tilanus HW, Kazemier G, van der Laan LJ.

    Hepatocyte-derived micrornas as serum biomarker of hepatic injury and rejection after liver transplantation. ***Liver Transplantation***. 2012, 18(3):290-7. (IF: **5.8**, **Q1**)

193. **Pan Q**, Peppelenbosch MP, Janssen HL, de Knegt RJ.

    The telaprevir/boceprevir era: from bench to bed and back. ***World J Gastroenterol***. 2012, 2012 Nov 21;18(43):6183-8. (IF: **5.7**)

194. **Pan Q**, van der Laan LJ.

    New targets for treatment against HCV infection. ***Best Practice & Research Clinical Gastroenterology***. 2012 Aug;26(4):505-15. (IF: **3**)

**2011**

195. **Pan Q**, Tilanus HW, Janssen HL, van der Laan LJ.

    Ribavirin enhances interferon-stimulated gene transcription by activation of the interferon-stimulated response element. ***Hepatology***. 2011, 53(4):1400-1401. (IF: **17.4**; top**10%**)

196. **Pan Q**, Fouraschen SM, Kaya FS, Verstegen MM, Pescatori M, Stubbs AP, van Ijcken W, van der Sloot A, Smits R, Kwekkeboom J, Metselaar HJ, Kazemier G, de Jonge J, Tilanus HW, Wagemaker G, Janssen HL, van der Laan LJ.

    Mobilization of hepatic mesenchymal stem cells from adult human liver grafts. ***Liver Transplantation***.

2011, 17(5):596-609. (IF: **5.8**, **Q1**)

197. **Pan Q**, de Ruiter PE, von Eije KJ, Smits R, Kwekkeboom J, Tilanus HW, Berkhout B, Janssen HL, van der Laan LJ.

Disturbance of the microRNA pathway by commonly used lentiviral shRNA libraries limits the application for screening host factors involved in hepatitis C virus infection. ***FEBS Letters***. 2011, 6;585(7):1025-1030. (IF: **4.1**)

198. van der Laan LJ, Wang Y, Tilanus HW, Janssen HL, **Pan Q***.

AAV-mediated gene therapy for liver diseases: the prime associate for clinical application? ***Expert Opin Biol Ther***. 2011 Mar;11(3):315-327. (IF: **4.4**)

**2010**

199. **Pan Q**, Metselaar HJ, de Ruiter P, Kwekkeboom J, Tilanus HW, Janssen HL, van der Laan LJ.

Calcineurin inhibitor tacrolimus does not interfere with the suppression of hepatitis C virus infection by interferon-alpha. ***Liver Transplantation***. 2010, 16(4):520-6. (IF: **5.8**, **Q1**)

**2009**

200. **Pan Q**, Henry SD, Metselaar HJ, Scholte B, Kwekkeboom J, Tilanus HW, Janssen HL, van der Laan LJ.

Combined anti-viral activity of interferon-alpha and RNA interference directed against hepatitis C without affecting vector delivery and gene silencing. ***J Mol Med***. 2009, 87(7):713-22. (IF: **4.6**)

201. **Pan Q**, Tilanus HW, Janssen HL, van der Laan LJ.

Prospects of RNAi and microRNA-based therapies for hepatitis C. ***Expert Opin Biol Ther***. 2009, 9:713-24. (IF: **4.4**)

**2008**

202. **Pan Q**, Liu B, Liu J, Cai R, Liu X, Qian C.

Synergistic antitumor activity of XIAP-shRNA and TRAIL expressed by oncolytic adenoviruses in experimental HCC. ***Acta Oncol***. 2008; 47(1): 135-44. (IF: **4.1**)

**2007**

203. **Pan QW**, Zhong SY, Liu BS, Liu J, Cai R, Wang YG, Liu XY, Qian C.

Enhanced sensitivity of hepatocellular carcinoma cells to chemotherapy with a Smac-armed oncolytic adenovirus. ***Acta Pharmacol Sin***. 2007, 28(12):1996-2004. (IF: **6.2**; **Q1**)

204. **Pan QW**, Henry SD, Scholte BJ, Tilanus HW, Janssen HL, van der Laan LJ.

New therapeutic opportunities for hepatitis C based on small RNA. ***World J Gastroenterol***. 2007 Sep 7;13(33):4431-6. (IF: **5.7**)

205. **Pan Q**, Liu B, Liu J, Cai R, Wang Y, Qian C.

Synergistic induction of tumor cell death by combining cisplatin with an oncolytic adenovirus carrying TRAIL. ***Mol Cell Biochem***. 2007, 304 (1-2):315-23**.** (IF: **3.4**)

**2006**

206. **Pan Q**, Cai R, Liu X, Qian C.

A novel strategy for cancer gene therapy: RNAi. ***Chinese Science Bulletin***. 2006, 51:91-97. (IF: **1.6**)

*National (Abstract in English and main text in Chinese)*

1. **Qiuwei Pan**, Rong Cai and Cheng Qian. Evaluation of the safety of AAV vector. ***International Journal of Virology***. 2006,13:5-8.
2. **Qiuwei Pan**, Rong cai, Xinyuan Liu and Cheng Qian. MicroRNA and cancer: Oncogenesis, Diagnosis and Therapy. ***Chinese Journal of Nature***. 2006, 28:84-87.
3. Chen Q, **Pan Q**, Cai R, Qian C. Prospects of RNA Interference Induced by RNA Pol II Promoter in Cancer Therapy. ***Progress in Biochemistry and Biophysics***. 2007. 34 (8): 806-815.

*Book chapters*

1. Pratika Y. Hernanda, Maikel P. Peppelenbosch and **Qiuwei Pan**. Chapter 28 - The implications of multipotent mesenchymal stromal cells in tumor biology and therapy – Book - The Biology and

Therapeutic Application of Mesenchymal Cells. Ed. K. Atkinson. John Wiley and Sons, Inc. 2017.

2. Monique M.A. Verstegen, **Qiuwei Pan** and Luc J.W. van der Laan. Chapter 1 - Gene Therapies for Hepatitis C Virus – Book "Gene Therapy for HIV and Chronic Infections", published by Springer 2015, ISBN 978-1-4939-2431-8.
3. **Qiuwei Pan** and Luc van der Laan. Hepatitis C: New Insights and Therapeutics by RNAi. Chapter 9 of the book ***"RNA Interference and Viruses: Current Innovations and Future Trends"***. Edited by: Miguel Angel Martínez. Caister Academic Press ISBN978-1-904455-56-1. 2010.
4. Scot Henry, **Qiuwei Pan** and Luc J.W. van der Laan. Production of multicopy shRNA lentiviral vectors for antiviral therapy. Book chapter in ***"Antiviral RNAi: Immune defense and therapy"*** Edited by: Ronald van Rij. Publisher: Humana Press. 2011. (Pubmed version: Methods Mol Biol. 2011;721:313-332.)